Intestinal Research

Original Articles

Maternal and fetal outcomes in pregnant Japanese women with inflammatory bowel disease: our experience with a series of 23 cases: Naoki Minami, Minoru Matsuura, Yorimitsu Koshikawa, Satoshi Yamada, Yusuke Honzawa, Shuji Yamamoto, Hiroshi Nakase; Intest Res 2017;15(1):90-96. Published online January 31, 2017; DOI: https://doi.org/10.5217/ir.2017.15.1.90

Background/Aims

Our physicians work to expand the possibilities to treat female patients with inflammatory bowel disease (IBD) who wish to become pregnant. Although many drugs, including 5-aminosalicylate (5-ASA), corticosteroids, immunomodulators, and biologics, are used safely during pregnancy, few reports have described the therapeutic regimen throughout pregnancy and the management of patients who relapse during pregnancy precisely. The aim of this study was to assess the management of patients with IBD during pregnancy.

Methods

We identified 19 patients (five with Crohn's disease and 14 with ulcerative colitis [UC]) who became pregnant with a total of 23 pregnancies between May 2005 and May 2015 by reviewing the medical records of Kyoto University Hospital. The following data were collected: the maternal variables, the IBD treatment type, the disease activity, the pregnancy outcome, and the mode of delivery.

Results

Among the 19 patients, 18 had become pregnant after being diagnosed with IBD, while one had developed UC newly after pregnancy. Throughout the gestation, all patients were treated with probiotics, 5-ASA, prednisolone, cytapheresis, or infliximab. The relapse rate during pregnancy was 21.7% (5/23 cases). The five patients who experienced a relapse were able to pursue their pregnancy after intensification of their treatments. There were no adverse fetal or neonatal problems, except in one case that required an emergency Caesarean section because of placental dysfunction and in which a very low-birth-weight infant was born preterm.

Conclusions

Our present data confirmed that even if the disease flares up during pregnancy, good pregnancy outcomes can be achieved with an optimal intensification of the patient's treatment.

Citations

Citations to this article as recorded by

The pregnancy outcome and drug usage during pregnancy among Taiwanese inflammatory bowel disease patients
Chen‐Wang Chang, Shu‐Chen Wei, Jen‐Wei Chou, Tien‐Yu Huang, Chia‐Jung Kuo, Wen‐Hung Hsu, Chen‐Shuan Chung, Tzu‐Chi Hsu, Wei‐Chen Lin, Ming‐Jen Chen, Horng‐Yuan Wang
Advances in Digestive Medicine.2023; 10(4): 226. CrossRef
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur, H. J. M. J. Crijns
Drugs.2020; 80(16): 1699. CrossRef

5,706 View
79 Download
2 Web of Science
2 Crossref

Analysis of the clinical indications for opiate use in inflammatory bowel disease: Youran Gao, Sundas Khan, Meredith Akerman, Keith Sultan; Intest Res 2017;15(1):83-89. Published online January 31, 2017; DOI: https://doi.org/10.5217/ir.2017.15.1.83

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

Opiate use for inflammatory bowel disease (IBD), particularly high-dose (HD) use, is associated with increased mortality. It's assumed that opiate use is directly related to IBD-related complaints, although this hasn't been well defined. Our goal was to determine the indications for opiate use as a first step in developing strategies to prevent or decrease opiate use.

Methods

A retrospective cohort was formed of adults who were diagnosed with IBD and for whom outpatient evaluations from 2009 to 2014 were documented. Opiate use was defined if opiates were prescribed for a minimum of 30 days over a 365-day period. Individual chart notes were then reviewed to determine the clinical indication(s) for low-dose (LD) and HD opiate use.

Results

After a search of the electronic records of 1,109,277 patients, 3,226 patients with IBD were found. One hundred four patients were identified as opiate users, including 65 patients with Crohn's and 39 with ulcerative colitis; a total of 134 indications were available for these patients. IBD-related complaints accounted for 49.25% of the opiate indications, with abdominal pain (23.13%) being the most common. Overall, opiate use for IBD-related complaints (81.40% vs. 50.82%; P=0.0014) and abdominal pain (44.19% vs. 19.67%; P=0.0071) was more common among HD than among LD.

Conclusions

Our findings show that most IBD patients using opiates, particularly HD users, used opiates for IBD-related complaints. Future research will need to determine the degree to which these complaints are related to disease activity and to formulate non-opiate pain management strategies for patients with both active and inactive IBD.

Citations

Citations to this article as recorded by

Integrated Single-Cell Transcriptome Analysis Reveals Novel Insights into the Role of Opioid Signaling in the Pathophysiology of Inflammatory Bowel Disease
Mudan Zhang, Zhuo Xie, Shenghong Zhang, Gaoshi Zhou
Biomedicines.2025; 13(6): 1398. CrossRef
Opioid Legislation in Patients With Inflammatory Bowel Disease: A State-wide Retrospective Cohort Study
Waseem Ahmed, Wade Billing, Timothy E Stump, Thomas Strobel, Sashidhar Sagi, Monika Fischer, Mathew Bohm
Inflammatory Bowel Diseases.2023; 29(9): 1355. CrossRef
Opioid use and associated factors in 1676 patients with inflammatory bowel disease: a multicentre quality improvement project
Samantha Baillie, Jimmy K Limdi, Ash Bassi, Aileen Fraser, Gareth Parkes, Glyn Scott, Tim Raine, Christopher A Lamb, Nicholas A Kennedy, Natalia Fumis, Melissa A Smith, Andrew Nicolaou, Holly Emms, John Wye, Anouk Lehmann, Isabel Carbery, James Goodhand,
Frontline Gastroenterology.2023; 14(6): 497. CrossRef
Abdominal pain in quiescent inflammatory bowel disease
Matthew D. Coates, Ansh Johri, Venkata Subhash Gorrepati, Parth Maheshwari, Shannon Dalessio, Vonn Walter, August Stuart, Walter Koltun, Nana Bernasko, Andrew Tinsley, Emmanuelle D. Williams, Kofi Clarke
International Journal of Colorectal Disease.2021; 36(1): 93. CrossRef
High-Dose Opioid Use Among Veterans with Unexplained Gastrointestinal Symptoms Versus Structural Gastrointestinal Diagnoses
Salva N. Balbale, Lishan Cao, Itishree Trivedi, Jonah J. Stulberg, Katie J. Suda, Walid F. Gellad, Charlesnika T. Evans, Bruce L. Lambert, Neil Jordan, Laurie A. Keefer
Digestive Diseases and Sciences.2021; 66(11): 3938. CrossRef
Opioid Use Among Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Blake Niccum, Oluwatoba Moninuola, Kaia Miller, Hamed Khalili
Clinical Gastroenterology and Hepatology.2021; 19(5): 895. CrossRef
Pain in Inflammatory Bowel Disease Is Not Improved During Hospitalization: The Impact of Opioids on Pain and Healthcare Utilization
Sameer K. Berry, Will Takakura, Catherine Bresee, Gil Y. Melmed
Digestive Diseases and Sciences.2020; 65(6): 1777. CrossRef
Predictors of mortality in inflammatory bowel disease patients treated for pneumonia
Offir Ukashi, Yifatch Barash, Michael J. Segel, Bella Ungar, Shelly Soffer, Shomron Ben-Horin, Eyal Klang, Uri Kopylov
Therapeutic Advances in Gastroenterology.2020;[Epub] CrossRef
Integrated Psychological Care is Needed, Welcomed and Effective in Ambulatory Inflammatory Bowel Disease Management: Evaluation of a New Initiative
Taryn Lores, Charlotte Goess, Antonina Mikocka-Walus, Kathryn L Collins, Anne L J Burke, Anna Chur-Hansen, Paul Delfabbro, Jane M Andrews
Journal of Crohn's and Colitis.2019; 13(7): 819. CrossRef

6,324 View
49 Download
9 Web of Science
9 Crossref

15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue: Dong-Hoon Yang, Yeon-Mi Ryu, Sun-Mi Lee, Jin-Yong Jeong, Soon Man Yoon, Byong Duk Ye, Jeong-Sik Byeon, Suk-Kyun Yang, Seung-Jae Myung; Intest Res 2017;15(1):75-82. Published online January 31, 2017; DOI: https://doi.org/10.5217/ir.2017.15.1.75

Abstract PDF PubReader ePub

Background/Aims

Cyclooxygenase-2 (COX-2), 15-hydroxyprostaglandin dehydrogenase (15-PGDH), and microsomal prostaglandin E synthase-1 (mPGEs-1) regulate prostaglandin E₂ (PGE₂) expression and are involved in colon carcinogenesis. We investigated the expression of PGE₂ and its regulating genes in sporadic human colon tumors and matched normal tissues.

Methods

Twenty colonic adenomas and 27 colonic adenocarcinomas were evaluated. COX-2 and 15-PGDH expression was quantified by real-time polymerase chain reaction. The expression of PGE₂ and mPGEs-1 was measured using enzyme-linked immunosorbent assay and Western blotting, respectively.

Results

The expression of COX-2, mPGEs-1, and PGE₂ did not differ between the adenomas and matched distant normal tissues. 15-PGDH expression was lower in adenomas than in the matched normal colonic tissues (P<0.001). In adenocarcinomas, mPGEs-1 and PGE₂ expression was significantly higher (P<0.001 and P=0.020, respectively), and COX-2 expression did not differ from that in normal tissues (P=0.207). 15-PGDH expression was significantly lower in the normal colonic mucosa from adenocarcinoma patients than in the normal mucosa from adenoma patients (P=0.018).

Conclusions

Early inactivation of 15-PGDH, followed by activation of COX-2 and mPGEs-1, contributes to PGE₂ production, leading to colon carcinogenesis. 15-PGDH might be a novel candidate marker for early detection of field defects in colon carcinogenesis.

Citations

Citations to this article as recorded by

Plant-derived extracts or compounds for Helicobacter-associated gastritis: a systematic review of their anti-Helicobacter activity and anti-inflammatory effect in animal experiments
Danni Chen, Wenlai Wang, Xiangyun Chen, Ning Liang, Jiawang Li, Wei Ding, Hongrui Zhang, Zhen Yang, Hongxia Zhao, Zhenhong Liu
Chinese Medicine.2025;[Epub] CrossRef
Targeting cyclooxygenase-2 for chemoprevention of inflammation-associated intestinal carcinogenesis: An update
Kyung-Soo Chun, Eun-Hee Kim, Do-Hee Kim, Na-Young Song, Wonki Kim, Hye-Kyung Na, Young-Joon Surh
Biochemical Pharmacology.2024; 228: 116259. CrossRef
Dietary intake of walnut prevented Helicobacter pylori-associated gastric cancer through rejuvenation of chronic atrophic gastritis
Jong Min Park, Young Min Han, Yong Jin Park, Ki Baik Hahm
Journal of Clinical Biochemistry and Nutrition.2021; 68(1): 37. CrossRef
Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials
Nagendra S. Yarla, Venkateshwar Madka, Gopal Pathuri, Chinthalapally V. Rao
International Journal of Molecular Sciences.2020; 21(24): 9609. CrossRef
A glance at…antioxidant and antiinflammatory properties of dietary cobalt
Michael J. Glade, Michael M. Meguid
Nutrition.2018; 46: 62. CrossRef
The prostanoid pathway contains potential prognostic markers for glioblastoma
Alexandros Theodoros Panagopoulos, Renata Nascimento Gomes, Fernando Gonçalves Almeida, Felipe da Costa Souza, José Carlos Esteves Veiga, Anna Nicolaou, Alison Colquhoun
Prostaglandins & Other Lipid Mediators.2018; 137: 52. CrossRef

6,095 View
54 Download
7 Web of Science
6 Crossref

Single fecal microbiota transplantation failed to change intestinal microbiota and had limited effectiveness against ulcerative colitis in Japanese patients: Shinta Mizuno, Kosaku Nanki, Katsuyoshi Matsuoka, Keiichiro Saigusa, Keiko Ono, Mari Arai, Shinya Sugimoto, Hiroki Kiyohara, Moeko Nakashima, Kozue Takeshita, Makoto Naganuma, Wataru Suda, Masahira Hattori, Takanori Kanai; Intest Res 2017;15(1):68-74. Published online January 31, 2017; DOI: https://doi.org/10.5217/ir.2017.15.1.68

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

Recent developments in analytical techniques including next-generation sequencing have clarified the correlation between intestinal microbiota and inflammatory bowel disease. Fecal microbiota transplantation (FMT) for patients with ulcerative colitis (UC) is proposed as a potential approach to resolving their dysbiosis; however, its safety and efficacy have not been confirmed. This single-arm, open-label, non-randomized study aimed to evaluate the safety and efficacy of FMT for Japanese patients with UC as the first registered clinical trial in Japan.

Methods

We enrolled 10 patients with active UC despite medical therapy. The donors were the patients' relatives and were carefully screened for infectious diseases. Fecal material was administered via colonoscopy, and the primary endpoint was the presence or absence of serious adverse events related to FMT. The secondary endpoint was a change in partial Mayo score at 12 weeks post-FMT. Scores ≤2 were considered a clinical response. Fecal samples were collected to follow changes in gut microbiota, while extracted complementary DNA were analyzed by a next-generation sequencer. We obtained written informed consent from all patients and donors. This study was approved by our Institutional Review Board and is registered in the University hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN 000012814).

Results

Five patients with moderate disease and five with severe disease were enrolled. No severe adverse effects were observed. One patient achieved clinical response; however, none of the patients' microbiota diversity recovered to the donor levels.

Conclusions

The use of single FMT for UC was safe; however, we failed to show its clinical efficacy and potential to change the intestinal microbiota.

Citations

Citations to this article as recorded by

Single-Donor and Pooling Strategies for Fecal Microbiota Transfer Product Preparation in Ulcerative Colitis: A Systematic Review and Meta-analysis
Benoît Levast, Mathieu Fontaine, Stéphane Nancey, Pierre Dechelotte, Joël Doré, Philippe Lehert
Clinical and Translational Gastroenterology.2023; 14(5): e00568. CrossRef
Recipient-independent, high-accuracy FMT-response prediction and optimization in mice and humans
Oshrit Shtossel, Sondra Turjeman, Alona Riumin, Michael R. Goldberg, Arnon Elizur, Yarin Bekor, Hadar Mor, Omry Koren, Yoram Louzoun
Microbiome.2023;[Epub] CrossRef
Transfer of FRozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial
Andreas Stallmach, Philip Grunert, Johannes Stallhofer, Bettina Löffler, Michael Baier, Jürgen Rödel, Michael Kiehntopf, Sophie Neugebauer, Dietmar H. Pieper, Howard Junca, Andrea Tannapfel, Ute Merkel, Ulrike Schumacher, Maria Breternitz-Gruhne, Tabitha
Trials.2022;[Epub] CrossRef
An updated systematic review and meta-analysis of fecal microbiota transplantation for the treatment of ulcerative colitis
Taobi Huang, Jinlan Xu, Maoying Wang, Ke Pu, Longquan Li, Huiyun Zhang, Yuan Liang, Weiming Sun, Yuping Wang
Medicine.2022; 101(30): e29790. CrossRef
Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease
Xiaochen Zhang, Dai Ishikawa, Toshifumi Ohkusa, Shinji Fukuda, Akihito Nagahara
Frontiers in Medicine.2022;[Epub] CrossRef
The Effects of Multi-Donor Fecal Microbiota Transplantation Capsules Combined with Thalidomide on Hormone-Dependent Ulcerative Colitis
Xiao-He Guo, Yan-Li Zhu, Lu Yang, Wen-Jing Li, Xue-Fang Du
Infection and Drug Resistance.2022; Volume 15: 7495. CrossRef
Fecal microbiota transplantation for ulcerative colitis
Katsuyoshi Matsuoka
Immunological Medicine.2021; 44(1): 30. CrossRef
Bacteriotherapy for inflammatory bowel disease
Yusuke Yoshimatsu, Yohei Mikami, Takanori Kanai
Inflammation and Regeneration.2021;[Epub] CrossRef
Repeated Fecal Microbial Transplantations and Antibiotic Pre-Treatment Are Linked to Improved Clinical Response and Remission in Inflammatory Bowel Disease: A Systematic Review and Pooled Proportion Meta-Analysis
Valentin Mocanu, Sabitha Rajaruban, Jerry Dang, Janice Y. Kung, Edward C. Deehan, Karen L. Madsen
Journal of Clinical Medicine.2021; 10(5): 959. CrossRef
Current status, complications and prospects of fecal microbiota transplantation therapy
Ohara Tadashi
Archives of Pathology and Clinical Research.2021; 5(1): 004. CrossRef
Fecal Microbial Transplantation in Critically Ill Patients—Structured Review and Perspectives
Ivana Cibulková, Veronika Řehořová, Jan Hajer, František Duška
Biomolecules.2021; 11(10): 1459. CrossRef
Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation
Herbert L. DuPont, Zhi-Dong Jiang, Andrew W. DuPont, Netanya S. Utay
Digestive Diseases and Sciences.2020; 65(3): 741. CrossRef
Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment
Xiao Yan Guo, Xin Juan Liu, Jian Yu Hao
Journal of Digestive Diseases.2020; 21(3): 147. CrossRef
Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis
Luciane de Fátima Caldeira, Helena H. Borba, Fernanda S. Tonin, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarolo, Udai P. Singh
PLOS ONE.2020; 15(9): e0238910. CrossRef
Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy
Ajit Sood, Arshdeep Singh, Vandana Midha, Ramit Mahajan, Dina Kao, David T Rubin, Charles N Bernstein
Crohn's & Colitis 360.2020;[Epub] CrossRef
Efficacy and safety of fecal microbiota transplantation for treating patients with ulcerative colitis: A systematic review and meta‐analysis
Hai Lan Zhao, Shu Zhen Chen, Hao Ming Xu, You Lian Zhou, Jie He, Hong Li Huang, Jing Xu, Yu Qiang Nie
Journal of Digestive Diseases.2020; 21(10): 534. CrossRef
Fecal Microbiota Transplantation in Intestinal Disorders: A Primer for Physicians
Ajit Sood, Vandana Midha, Harmeet Kaur, Arshdeep Singh
Journal of Gastrointestinal Infections.2020; 10(1): 16. CrossRef
Multi-session fecal microbiota transplantation using colonoscopy has favorable outcomes for the treatment of steroid-dependent ulcerative colitis
Young-Seok Cho
Intestinal Research.2019; 17(1): 6. CrossRef
RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention
Jung Hoon Song, You Sun Kim
Gut and Liver.2019; 13(1): 16. CrossRef
1) Microbiota and Gastrointestinal Diseases
Takanori Kanai
Nihon Naika Gakkai Zasshi.2019; 108(3): 401. CrossRef
Fecal microbial transplantation
Sonia Bouri, Ailsa Hart
Current Opinion in Clinical Nutrition & Metabolic Care.2018; 21(5): 405. CrossRef
The Value of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis
Yantian Cao, Bangjie Zhang, Yuanyuan Wu, Qingzhi Wang, Jie Wang, Fangfang Shen
Gastroenterology Research and Practice.2018; 2018: 1. CrossRef
Gut microbiota‐immune‐brain interactions in chemotherapy‐associated behavioral comorbidities
Kelley R. Jordan, Brett R. Loman, Michael T. Bailey, Leah M. Pyter
Cancer.2018; 124(20): 3990. CrossRef
Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation
Seong Ran Jeon, Jocelyn Chai, Christiana Kim, Christine H. Lee
Current Infectious Disease Reports.2018;[Epub] CrossRef
Is there a potential role of fecal microbiota transplantation in the treatment of inflammatory bowel disease?
Chang Soo Eun
Intestinal Research.2017; 15(2): 145. CrossRef
Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome
Shinta Mizuno, Tatsuhiro Masaoka, Makoto Naganuma, Taishiro Kishimoto, Momoko Kitazawa, Shunya Kurokawa, Moeko Nakashima, Kozue Takeshita, Wataru Suda, Masaru Mimura, Masahira Hattori, Takanori Kanai
Digestion.2017; 96(1): 29. CrossRef
Intestinal immune response is regulated by gut microbe
Shun TANEMOTO, Tomohisa SUJINO, Takanori KANAI
Japanese Journal of Clinical Immunology.2017; 40(6): 408. CrossRef

8,511 View
98 Download
26 Web of Science
27 Crossref

The submucosal fibrosis: what does it mean for colorectal endoscopic submucosal dissection?: Eun Kyoung Kim, Dong Soo Han, Youngouk Ro, Chang Soo Eun, Kyo-Sang Yoo, Young-Ha Oh; Intest Res 2016;14(4):358-364. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.358

Abstract PDF PubReader

Background/Aims

Endoscopic submucosal dissection (ESD) allows removal of colorectal epithelial neoplasms en bloc regardless of size. Colorectal ESD is a difficult procedure because of technical difficulties and risks of complications. This study aimed to assess the relationship between ESD outcome and degree of submucosal fibrosis.

Methods

Patients with colorectal tumors undergoing ESD and their medical records were reviewed retrospectively. The degree of submucosal fibrosis was classified into three types. The relationship between ESD outcome and degree of submucosal fibrosis was analyzed.

Results

ESD was performed in 158 patients. Thirty-eight cases of F0 (no) fibrosis (24.1%) and 46 cases of F2 (severe) fibrosis (29.1%) were observed. Complete resection was achieved for 138 lesions (87.3%). Multivariate analysis demonstrated that submucosal invasion of tumor and histology of carcinoma were independent risk factors for F2 fibrosis. Severe fibrosis was an independent risk factor for incomplete resection.

Conclusions

Severe fibrosis is an important factor related to incomplete resection during colorectal ESD. In cases of severe fibrosis, the rate of complete resection was low even when ESD was performed by an experienced operator. Evaluation of submucosal fibrosis may be helpful to predict the submucosal invasion of tumors and technical difficulties in ESD.

Citations

Citations to this article as recorded by

Learning curve of colorectal endoscopic submucosal dissection of an endoscopist experienced hands‐on training in Japan
Sukit Pattarajierapan, Yutaka Saito, Hiroyuki Takamaru, Naoya Toyoshima, Naruemon Wisedopas, Natcha Wanpiyarat, Nathawadee Lerttanatum, Supakij Khomvilai
Journal of Gastroenterology and Hepatology.2025; 40(1): 226. CrossRef
Feasibility, safety and efficacy of endoscopic submucosal dissection for recurrent superficial rectal neoplastic lesions after transanal microsurgery
Ali Jaafar, Jeremie Jacques, Sarah Leblanc, Romain Legros, Vincent Lepilliez, Arthur Berger, Edouard Chabrun, Yann Le Baleur, Mathieu Pioche, Maximilien Barret, Timothee Wallenhorst, Thibault Degand, Felix Corre, Marion Schaefer, Xavier Dray
Digestive and Liver Disease.2025; 57(1): 68. CrossRef
Risk Factors for Perforation in Endoscopic Treatment for Early Colorectal Cancer: A Nationwide ENTER-K Study
Ik Hyun Jo, Hyun Gun Kim, Young-Seok Cho, Hyun Jung Lee, Eun Ran Kim, Yoo Jin Lee, Sung Wook Hwang, Kyeong-Ok Kim, Jun Lee, Hyuk Soon Choi, Yunho Jung, Chang Mo Moon
Gut and Liver.2025; 19(1): 95. CrossRef
Outcomes of Colonic Endoscopic Submucosal Dissection and Advanced Tissue Resection in Obese Patients: An Analysis of a Large Western Cohort
Tara Keihanian, Mai Khalaf, Fares Ayoub, Elaheh Keivani Boroujeni, Salmaan A. Jawaid, Mohamed O. Othman
Digestive Diseases and Sciences.2025; 70(6): 2117. CrossRef
Comparing Precutting Endoscopic Mucosal Resection Using Snare-Tip and Endoscopic Submucosal Dissection Knife for Large Nonpedunculated Colorectal Polyps: A Randomized Controlled Trial
Chang Kyo Oh, Young Wook Cho, Young-Seok Cho
American Journal of Gastroenterology.2025;[Epub] CrossRef
Delays in definitive endoscopic resection of previously manipulated colorectal polyps as a risk factor for inferior resection outcomes
Fares Ayoub, Grace E. Kim, Wenfei Wang, Dennis Chen, Uzma D. Siddiqui
Gastrointestinal Endoscopy.2024; 100(1): 109. CrossRef
Is there a best choice of equipment for colorectal endoscopic submucosal dissection?
Francesco Cocomazzi, Sonia Carparelli, Nunzia Labarile, Antonio Capogreco, Marco Gentile, Roberta Maselli, Jahnvi Dhar, Jayanta Samanta, Alessandro Repici, Cesare Hassan, Francesco Perri, Antonio Facciorusso
Expert Review of Medical Devices.2024; 21(7): 561. CrossRef
Risk Factors for Post-Endoscopic Submucosal Dissection Electrocoagulation Syndrome in Patients with Colorectal Neoplasms: A Multicenter, Large-Scale, Retrospective Cohort Study by the Honam Association for the Study of Intestinal Disease (HASID)
Hyo-Yeop Song, Seong-Jung Kim, Jun Lee, Byung Chul Jin, Dong Hyun Kim, Hyun-Soo Kim, Hyung-Hoon Oh, Young-Eun Joo, Dae-Seong Myung, Sang-Wook Kim, Geom-Seog Seo
Journal of Clinical Medicine.2024; 13(13): 3932. CrossRef
Hybrid Versus Conventional Colorectal Endoscopic Submucosal Dissection: A Multicenter Randomized Controlled Trial (Short-Endoscopic Submucosal Dissection)
Dennis Yang, Muhammad K. Hasan, Salmaan Jawaid, Gurdeep Singh, Yasi Xiao, Mai Khalaf, Yutaka Tomizawa, Neil S. Sharma, Peter V. Draganov, Mohamed O. Othman
American Journal of Gastroenterology.2024; 119(12): 2436. CrossRef
The Derivation and External Validation of a Fibrosis Risk Model for Colorectal Tumours Undergoing Endoscopic Submucosal Dissection
Sandro Sferrazza, Marcello Maida, Giulio Calabrese, Antonio Facciorusso, Lorenzo Fuccio, Leonardo Frazzoni, Roberta Maselli, Alessandro Repici, Roberto Di Mitri, João Santos-Antunes
Journal of Clinical Medicine.2024; 13(15): 4517. CrossRef
Development and validation of a predictive model for submucosal fibrosis in patients with early gastric cancer undergoing endoscopic submucosal dissection: experience from a large tertiary center
Yunqing Zeng, Jinhou Li, Yuan Zheng, Di Zhang, Ning Zhong, Xiuli Zuo, Yanqing Li, Wenbin Yu, Jiaoyang Lu
Annals of Medicine.2024;[Epub] CrossRef
Comparing underwater endoscopic submucosal dissection and conventional endoscopic submucosal dissection for large laterally spreading tumor: a randomized controlled trial (with video)
Chang Kyo Oh, Hwe Hoon Chung, Jae Keun Park, Jiyoon Jung, Hee Yeon Lee, Yu Jin Kim, Jin Bae Kim
Gastrointestinal Endoscopy.2024; 100(6): 1079. CrossRef
Outcomes and Learning Curve in Endoscopic Submucosal Dissection of Rectal Neoplasms with Severe Fibrosis: Experience of a Western Center
Catarina Félix, Pedro Barreiro, Rui Mendo, André Mascarenhas, Cristina Chagas
GE - Portuguese Journal of Gastroenterology.2023; 30(3): 221. CrossRef
Endoscopic submucosal dissection for colorectal polyps: outcome determining factors
Chi Woo Samuel Chow, Tak Lit Derek Fung, Pak Tat Chan, Kam Hung Kwok
Surgical Endoscopy.2023; 37(2): 1293. CrossRef
Safety and feasibility of same-day discharge after endoscopic submucosal dissection: a Western multicenter prospective cohort study
William King, Peter Draganov, V.Subhash Gorrepati, Maham Hayat, Hiroyuki Aihara, Michael Karasik, Saowanee Ngamruengphong, Abdul Aziz Aadam, Mohamed O. Othman, Neil Sharma, Ian S. Grimm, Alaa Rostom, B. Joseph Elmunzer, Dennis Yang
Gastrointestinal Endoscopy.2023; 97(6): 1045. CrossRef
Is colorectal endoscopic submucosal dissection safe and effective for 15–19-mm tumors?
Yunho Jung, Young Hwangbo, Young Sin Cho, Seong Woo Choi, Seong Ran Jeon, Hyun Gun Kim, Bong Min Ko, Jin-O Kim
International Journal of Colorectal Disease.2023;[Epub] CrossRef
Initial multicenter experience using a novel articulating through-the-scope traction device for endoscopic submucosal dissection
Maham Hayat, Alexander Schlachterman, Grace Schiavone, Meir Mizrahi, Jong Kyu Park, Vivek Kumbhari, Antonio Cheesman, Peter V Draganov, Muhammad Khalid Hasan, Dennis Yang
Endoscopy International Open.2023; 11(08): E778. CrossRef
Novel beagle model of gastric local fibrotic target lesions for the evaluation and training of endoscopic techniques
Xiao-Jian He, Xiao-Ling Wang, Chuan-Shen Jiang, Dong-Gui Hong, Hai-Lan Lin, Yun-Ping Zheng, Han Li, Xin-Jiang Chen, Jian-Xiao Huang, Ling-Shuang Dai, Mei-Yan Liu, Bao-Xiang Luo, Dong-Liang Li, Da-Zhou Li, Wen Wang
BMC Gastroenterology.2023;[Epub] CrossRef
Comparison of precutting endoscopic mucosal resection and endoscopic submucosal dissection for large (20–30 mm) flat colorectal lesions
Chang Kyo Oh, Young Wook Cho, In Hyoung Choi, Han Hee Lee, Chul‐Hyun Lim, Jin Su Kim, Bo‐In Lee, Young‐Seok Cho
Journal of Gastroenterology and Hepatology.2022; 37(3): 568. CrossRef
Endoscopic Submucosal Dissection in North America: A Large Prospective Multicenter Study
Peter V. Draganov, Hiroyuki Aihara, Michael S. Karasik, Saowanee Ngamruengphong, Abdul Aziz Aadam, Mohamed O. Othman, Neil Sharma, Ian S. Grimm, Alaa Rostom, B. Joseph Elmunzer, Salmaan A. Jawaid, Donevan Westerveld, Yaseen B. Perbtani, Brenda J. Hoffman,
Gastroenterology.2021; 160(7): 2317. CrossRef
Pocket-creation method improves efficacy of colorectal endoscopic submucosal dissection: a system review and meta-analysis
Jian Gong, Tong Chen, Yuyong Tan, Deliang Liu
European Journal of Gastroenterology & Hepatology.2021; 33(10): 1241. CrossRef
Impact of Procedure Time of Preceding Endoscopic Submucosal Dissection on the Difficulty of Laparoscopic Rectal Surgery
Hiroaki Nozawa, Kazushige Kawai, Kazuhito Sasaki, Shigenobu Emoto, Koji Murono, Hirofumi Sonoda, Hiroaki Ishii, Soichiro Ishihara
International Surgery.2021; 105(1-3): 528. CrossRef
Factors Associated with Fibrosis during Colorectal Endoscopic Submucosal Dissection: Does Pretreatment Biopsy Potentially Elicit Submucosal Fibrosis and Affect Endoscopic Submucosal Dissection Outcomes?
Masatake Kuroha, Hisashi Shiga, Yoshitake Kanazawa, Hiroshi Nagai, Tomoyuki Handa, Ryo Ichikawa, Motoyuki Onodera, Takeo Naito, Rintaro Moroi, Tomoya Kimura, Katsuya Endo, Yoichi Kakuta, Yoshitaka Kinouchi, Tooru Shimosegawa, Atsushi Masamune
Digestion.2021; 102(4): 590. CrossRef
Endoscopic submucosal dissection in rectal tumors extending or not to the dentate line: A comparative analysis
Déborah Roland, Gabriel Rahmi, Enrique Pérez-Cuadrado-Robles, Guillaume Perrod, Jérémie Jacques, Maximilien Barret, Sarah Leblanc, Arthur Berger, Jérémie Albouys, Stanislas Chaussade, Christophe Cellier
Digestive and Liver Disease.2020; 52(3): 296. CrossRef
Novel approach to endoscopic submucosal dissection of a cecal lesion with nonlifting sign by submucosal fatty tissue with use of selective-regulation high-pressure water-jet method and immersion in saline solution
Felipe Ramos-Zabala, Sabina Beg, Marian García-Mayor, Adolfo Parra-Blanco, Luis Moreno-Almazán
VideoGIE.2020; 5(3): 116. CrossRef
Review on colorectal endoscopic submucosal dissection focusing on the technical aspect
Tak Lit Derek Fung, Chi Woo Samuel Chow, Pak Tat Chan, Kam Hung Kwok
Surgical Endoscopy.2020; 34(9): 3766. CrossRef
Endoscopic Biopsy in Differential Diagnosis of Colorectal Serrated Lesions
K. D. Khalin, M. Yu. Agapov, L. V. Zvereva, K. V. Stegniy
Russian Journal of Gastroenterology, Hepatology, Coloproctology.2020; 30(3): 42. CrossRef
Predictors for Submucosal Fibrosis in Patients With Superficial Squamous Esophageal Neoplasia Undergoing Endoscopic Submucosal Dissection
Xiaoduan Zhuang, Ming Xu, Zhenyu Chen, Jianqi Wang, Kai Qian, Shihao Wang, Guoming Deng, Yang Bai
Clinical and Translational Gastroenterology.2020; 11(8): e00188. CrossRef
Hybrid resection with ESD and FTRD: Could this be a rescue treatment in the presence of severe submucosal fibrosis?
Gianluca Andrisani, Francesco Maria Di Matteo
Digestive and Liver Disease.2019; 51(4): 607. CrossRef
Factors Predictive of Complete Excision of Large Colorectal Neoplasia Using Hybrid Endoscopic Submucosal Dissection: A KASID Multicenter Study
Yunho Jung, Jong Wook Kim, Jeong-Sik Byeon, Hoon Sup Koo, Sun-Jin Boo, Jun Lee, Young Hwangbo, Yoon Mi Jeen, Hyun Gun Kim
Digestive Diseases and Sciences.2018; 63(10): 2773. CrossRef
Perforation and Postoperative Bleeding Associated with Endoscopic Submucosal Dissection in Colorectal Tumors: An Analysis of 398 Lesions Treated in Saga, Japan
Koji Yamamoto, Ryo Shimoda, Shinichi Ogata, Megumi Hara, Yoichiro Ito, Naoyuki Tominaga, Atsushi Nakayama, Yasuhisa Sakata, Nanae Tsuruoka, Ryuichi Iwakiri, Kazuma Fujimoto
Internal Medicine.2018; 57(15): 2115. CrossRef
The efficacy of the pocket-creation method for cases with severe fibrosis in colorectal endoscopic submucosal dissection
Naohisa Yoshida, Yuji Naito, Ritsu Yasuda, Takaaki Murakami, Ryohei Hirose, Kiyoshi Ogiso, Yutaka Inada, Hideyuki Konishi, Rafiz Abdul Rani, Mitsuo Kishimoto, Eiichi Konishi, Masayoshi Nakanishi, Yoshito Itoh
Endoscopy International Open.2018; 06(08): E975. CrossRef
Local recurrence and subsequent endoscopic treatment after endoscopic piecemeal mucosal resection with or without precutting in the colorectum
Myeongsook Seo, Eun Mi Song, Gwang Un Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Jeong-Sik Byeon
Intestinal Research.2017; 15(4): 502. CrossRef

6,270 View
60 Download
36 Web of Science
33 Crossref

A wide variation of the quality of colonoscopy reporting system in the real clinical practice in southeastern area of Korea: Jung Min Lee, Yu Jin Kang, Eun Soo Kim, Yoo Jin Lee, Kyung Sik Park, Kwang Bum Cho, Seong Woo Jeon, Min Kyu Jung, Hyun Seok Lee, Eun Young Kim, Jin Tae Jung, Byung Ik Jang, Kyeong Ok Kim, Yun Jin Chung, Chang Hun Yang; Intest Res 2016;14(4):351-357. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.351

Abstract PDF PubReader

Background/Aims

Establishment of a colonoscopy reporting system is a prerequisite to determining and improving quality. This study aimed to investigate colonoscopists' opinions and the actual situation of a colonoscopy reporting system in a clinical practice in southeastern area of Korea and to assess the factors predictive of an inadequate reporting system.

Methods

Physicians who performed colonoscopies in the Daegu-Gyeongbuk province of Korea and were registered with the Korean Society of Gastrointestinal Endoscopy (KSGE) were interviewed via mail about colonoscopy reporting systems using a standardized questionnaire.

Results

Of 181 endoscopists invited to participate, 125 responded to the questionnaires (response rate, 69%). Most responders were internists (105/125, 84%) and worked in primary clinics (88/125, 70.4%). Seventy-one specialists (56.8%) held board certifications for endoscopy from the KSGE. A median of 20 colonoscopies (interquartile range, 10–47) was performed per month. Although 88.8% of responders agreed that a colonoscopy reporting system is necessary, only 18.4% (23/125) had achieved the optimal reporting system level recommended by the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. One-third of endoscopists replied that they did not use a reporting document for the main reasons of "too busy" and "inconvenience." Non-endoscopy specialists and primary care centers were independent predictive factors for failure to use a colonoscopy reporting system.

Conclusions

The quality of colonoscopy reporting systems varies widely and is considerably suboptimal in actual clinical practice settings in southeastern Korea, indicating considerable room for quality improvements in this field.

Citations

Citations to this article as recorded by

Association of Poor Differentiation or Positive Vertical Margin with Residual Disease in Patients with Subsequent Colectomy after Complete Macroscopic Endoscopic Resection of Early Colorectal Cancer
Ki Ju Kim, Hyun Seok Lee, Seong Woo Jeon, Sun Jin, Sang Won Lee
Gastroenterology Research and Practice.2017; 2017: 1. CrossRef
Derivation and validation of a risk scoring model to predict advanced colorectal neoplasm in adults of all ages
Hyo‐Joon Yang, Sungkyoung Choi, Soo‐Kyung Park, Yoon Suk Jung, Kyu Yong Choi, Taesung Park, Ji Yeon Kim, Dong Il Park
Journal of Gastroenterology and Hepatology.2017; 32(7): 1328. CrossRef
Screening strategy for colorectal cancer according to risk
Dong Soo Han
Journal of the Korean Medical Association.2017; 60(11): 893. CrossRef

7,381 View
36 Download
3 Web of Science
3 Crossref

Symptomatic improvement with gluten restriction in irritable bowel syndrome: a prospective, randomized, double blinded placebo controlled trial: Vinay G Zanwar, Sunil V Pawar, Pravir A Gambhire, Samit S Jain, Ravindra G Surude, Vinaya B Shah, Qais Q Contractor, Pravin M Rathi; Intest Res 2016;14(4):343-350. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.343

Abstract PDF PubReader

Background/Aims

The existence of non-celiac gluten sensitivity has been debated. Indeed, the intestinal and extra-intestinal symptoms of many patients with irritable bowel syndrome (IBS) but without celiac disease or wheat allergy have been shown to improve on a gluten-free diet. Therefore, this study set out to evaluate the effects of gluten on IBS symptoms.

Methods

We performed a double-blind randomized placebo-controlled rechallenge trial in a tertiary care hospital with IBS patients who fulfilled the Rome III criteria. Patients with celiac disease and wheat allergy were appropriately excluded. The participants were administered a gluten-free diet for 4 weeks and were asked to complete a symptom-based questionnaire to assess their overall symptoms, abdominal pain, bloating, wind, and tiredness on the visual analog scale (0-100) at the baseline and every week thereafter. The participants who showed improvement were randomly assigned to one of two groups to receive either a placebo (gluten-free breads) or gluten (whole cereal breads) as a rechallenge for the next 4 weeks.

Results

In line with the protocol analysis, 60 patients completed the study. The overall symptom score on the visual analog scale was significantly different between the two groups (P<0.05). Moreover, the patients in the gluten intervention group scored significantly higher in terms of abdominal pain, bloating, and tiredness (P<0.05), and their symptoms worsened within 1 week of the rechallenge.

Conclusions

A gluten diet may worsen the symptoms of IBS patients. Therefore, some form of gluten sensitivity other than celiac disease exists in some of them, and patients with IBS may benefit from gluten restrictions.

Citations

Citations to this article as recorded by

The role of gluten and wheat in irritable bowel syndrome and noncoeliac gluten or wheat sensitivity
Tom van Gils, Magnus Simrén
Current Opinion in Gastroenterology.2025; 41(3): 164. CrossRef
Diet, nutraceuticals, and lifestyle interventions for the treatment and management of irritable bowel syndrome
Zoe N. Memel, Neha D. Shah, Kendall R. Beck
Nutrition in Clinical Practice.2025;[Epub] CrossRef
Gluten-free grains: Importance, processing and its effect on quality of gluten-free products
Samandeep Kaur, Kshitiz Kumar, Lochan Singh, Vijay Singh Sharanagat, Prabhat K. Nema, Vijendra Mishra, Bharat Bhushan
Critical Reviews in Food Science and Nutrition.2024; 64(7): 1988. CrossRef
Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology
Uday C. Ghoshal, Sanjeev Sachdeva, Nitesh Pratap, Arun Karyampudi, Uzma Mustafa, Philip Abraham, Chetan B. Bhatt, Karmabir Chakravartty, Sujit Chaudhuri, Omesh Goyal, Govind K. Makharia, Manas Kumar Panigrahi, Prasanta Kumar Parida, Sudhanshu Patwari, Raj
Indian Journal of Gastroenterology.2023; 42(2): 249. CrossRef
Current evidence for dietary therapies in irritable bowel syndrome
Anupam Rej, Hugo A. Penny
Current Opinion in Gastroenterology.2023; 39(3): 219. CrossRef
The Role of Gluten in Gastrointestinal Disorders: A Review
Sabrina Cenni, Veronica Sesenna, Giulia Boiardi, Marianna Casertano, Giuseppina Russo, Alfonso Reginelli, Susanna Esposito, Caterina Strisciuglio
Nutrients.2023; 15(7): 1615. CrossRef
Gluten restriction in irritable bowel syndrome, yes or no?: a GRADE-assessed systematic review and meta-analysis
Erfan Arabpour, Dorsa Alijanzadeh, Amir Sadeghi, Sina Khoshdel, Azita Hekmatdoost, Hamed Kord-Varkaneh, Mohammad Abdehagh
Frontiers in Nutrition.2023;[Epub] CrossRef
Boosting biomedical document classification through the use of domain entity recognizers and semantic ontologies for document representation: The case of gluten bibliome
Martín Pérez-Pérez, Tânia Ferreira, Anália Lourenço, Gilberto Igrejas, Florentino Fdez-Riverola
Neurocomputing.2022; 484: 223. CrossRef
Management of bloating
Jordi Serra
Neurogastroenterology & Motility.2022;[Epub] CrossRef
Evidence-Based and Emerging Diet Recommendations for Small Bowel Disorders
Anupam Rej, Michael D. E. Potter, Nicholas J. Talley, Ayesha Shah, Gerald Holtmann, David Surendran Sanders
American Journal of Gastroenterology.2022; 117(6): 958. CrossRef
Diet and irritable bowel syndrome: an update from a UK consensus meeting
A. Rej, A. Avery, I. Aziz, C. J. Black, R. K. Bowyer, R. L. Buckle, L. Seamark, C. C. Shaw, J. Thompson, N. Trott, M. Williams, D. S. Sanders
BMC Medicine.2022;[Epub] CrossRef
Belgian consensus on irritable bowel syndrome
S Kindt, H Louis, H De Schepper, J Arts, P Caenepeel, D De Looze, A Gerkens, T Holvoet, P Latour, T Mahler, F Mokaddem, S Nullens, H Piessevaux, P Poortmans, G Rasschaert, M Surmont, H Vafa, K Van Malderen, T Vanuytsel, F Wuestenberghs, J Tack
Acta Gastro Enterologica Belgica.2022; 85(2): 360. CrossRef
A food pyramid, based on a review of the emerging literature, for subjects with inflammatory bowel disease
Mariangela Rondanelli, Silvia Lamburghini, Milena A. Faliva, Gabriella Peroni, Antonella Riva, Pietro Allegrini, Daniele Spadaccini, Clara Gasparri, Giancarlo Iannello, Vittoria Infantino, Tariq A. Alalwan, Simone Perna, Alessandra Miccono
Endocrinología, Diabetes y Nutrición.2021; 68(1): 17. CrossRef
Non-responsive celiac disease may coincide with additional food intolerance/malabsorption, including histamine intolerance
Wolfgang J. Schnedl, Harald Mangge, Michael Schenk, Dietmar Enko
Medical Hypotheses.2021; 146: 110404. CrossRef
Non-celiac wheat sensitivity: rationality and irrationality of a gluten-free diet in individuals affected with non-celiac disease: a review
Consolato Sergi, Vincenzo Villanacci, Antonio Carroccio
BMC Gastroenterology.2021;[Epub] CrossRef
Personalizing Dietary Therapies For Irritable Bowel Syndrome: What Is Gluten’s Role?
Anupam Rej, Imran Aziz, David S. Sanders
Clinical Gastroenterology and Hepatology.2021; 19(11): 2270. CrossRef
A food pyramid, based on a review of the emerging literature, for subjects with inflammatory bowel disease
Mariangela Rondanelli, Silvia Lamburghini, Milena A. Faliva, Gabriella Peroni, Antonella Riva, Pietro Allegrini, Daniele Spadaccini, Clara Gasparri, Giancarlo Iannello, Vittoria Infantino, Tariq A. Alalwan, Simone Perna, Alessandra Miccono
Endocrinología, Diabetes y Nutrición (English ed.).2021; 68(1): 17. CrossRef
Histamine Intolerance Originates in the Gut
Wolfgang J. Schnedl, Dietmar Enko
Nutrients.2021; 13(4): 1262. CrossRef
Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms
Annamaria Altomare, Claudia Di Rosa, Elena Imperia, Sara Emerenziani, Michele Cicala, Michele Pier Luca Guarino
Nutrients.2021; 13(5): 1506. CrossRef
Adherence to treatment of patients with irritable bowel syndrome: state of the issue
S.A. Sukhanova, A.Yu. Timakova, M.A. Livzan, M.M. Fedorin, Yu.P. Skirdenko, O.V. Gaus, K.A. Andreev, A.V. Gorbenko, M.I. Plinder
Profilakticheskaya meditsina.2021; 24(8): 101. CrossRef
Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastr
P. Layer, V. Andresen, H. Allescher, S. C. Bischoff, M. Claßen, S. Elsenbruch, M. Freitag, T. Frieling, M. Gebhard, M. Goebel-Stengel, W. Häuser, G. Holtmann, J. Keller, M. E. Kreis, W. Kruis, J. Langhorst, P. Lynen Jansen, A. Madisch, H. Mönnikes, S. Mül
Zeitschrift für Gastroenterologie.2021; 59(12): 1323. CrossRef
Nutrition in Patients with Lactose Malabsorption, Celiac Disease, and Related Disorders
Michele J. Alkalay
Nutrients.2021; 14(1): 2. CrossRef
Letter: the gluten‐free diet as a bottom‐up approach for irritable bowel syndrome
Anupam Rej, Rachel Louise Buckle, Christian Charles Shaw, Nick Trott, Imran Aziz, David Surendran Sanders
Alimentary Pharmacology & Therapeutics.2020; 51(1): 184. CrossRef
Irritable Bowel Syndrome and Gluten-Related Disorders
Paolo Usai-Satta, Gabrio Bassotti, Massimo Bellini, Francesco Oppia, Mariantonia Lai, Francesco Cabras
Nutrients.2020; 12(4): 1117. CrossRef
Ernährungsmedizinische Aspekte beim Reizdarmsyndrom – ein Update
Larissa Hetterich, Andreas Stengel
Aktuelle Ernährungsmedizin.2020; 45(04): 276. CrossRef
The Two Faces of Wheat
Herbert Wieser, Peter Koehler, Katharina A. Scherf
Frontiers in Nutrition.2020;[Epub] CrossRef
Low Fermentable Oligo- Di- and Mono-Saccharides and Polyols (FODMAPs) or Gluten Free Diet: What Is Best for Irritable Bowel Syndrome?
Massimo Bellini, Sara Tonarelli, Maria Gloria Mumolo, Francesco Bronzini, Andrea Pancetti, Lorenzo Bertani, Francesco Costa, Angelo Ricchiuti, Nicola de Bortoli, Santino Marchi, Alessandra Rossi
Nutrients.2020; 12(11): 3368. CrossRef
Breaking bread!
Anupam Rej, Imran Aziz, David Surendran Sanders
Proceedings of the Nutrition Society.2019; 78(1): 118. CrossRef
Efficacy of the gluten free diet in the management of functional gastrointestinal disorders: a systematic review on behalf of the Italian Society of Paediatrics
Elena Scarpato, Renata Auricchio, Francesca Penagini, Angelo Campanozzi, Gian Vincenzo Zuccotti, Riccardo Troncone
Italian Journal of Pediatrics.2019;[Epub] CrossRef
The overlap of irritable bowel syndrome and noncoeliac gluten sensitivity
Anupam Rej, David S. Sanders
Current Opinion in Gastroenterology.2019; 35(3): 199. CrossRef
Gluten Vehicle and Placebo for Non-Celiac Gluten Sensitivity Assessment
Oscar Gerardo Figueroa-Salcido, Noé Ontiveros, Francisco Cabrera-Chavez
Medicina.2019; 55(5): 117. CrossRef
The role of diet in irritable bowel syndrome: implications for dietary advice
A. Rej, I. Aziz, H. Tornblom, D. S. Sanders, M. Simrén
Journal of Internal Medicine.2019; 286(5): 490. CrossRef
Does Irritable Bowel Syndrome Exist? Identifiable and Treatable Causes of Associated Symptoms Suggest It May Not
Benjamin I. Brown
Gastrointestinal Disorders.2019; 1(3): 314. CrossRef
Extra-intestinal manifestations of non-celiac gluten sensitivity: An expanding paradigm
Giuseppe Losurdo, Mariabeatrice Principi, Andrea Iannone, Annacinzia Amoruso, Enzo Ierardi, Alfredo Di Leo, Michele Barone
World Journal of Gastroenterology.2018; 24(14): 1521. CrossRef
Is an enzyme supplement for celiac disease finally on the cards?
Julia König, Robert J. Brummer
Expert Review of Gastroenterology & Hepatology.2018; 12(6): 531. CrossRef
Non-celiac gluten sensitivity: people without celiac disease avoiding gluten—is it due to histamine intolerance?
Wolfgang J. Schnedl, Sonja Lackner, Dietmar Enko, Michael Schenk, Harald Mangge, Sandra J. Holasek
Inflammation Research.2018; 67(4): 279. CrossRef
Gluten sensitivities and the allergist: Threshing the grain from the husks
J. G. Burkhardt, A. Chapa‐Rodriguez, S. L. Bahna
Allergy.2018; 73(7): 1359. CrossRef
Prevalence and factors associated with gluten sensitivity in inflammatory bowel disease
Berkeley N. Limketkai, Rachel Sepulveda, Tressia Hing, Neha D. Shah, Monica Choe, David Limsui, Shamita Shah
Scandinavian Journal of Gastroenterology.2018; 53(2): 147. CrossRef
Non‐celiac gluten or wheat sensitivity: It's complicated!
Maria I. Pinto‐Sanchez, Elena F. Verdu
Neurogastroenterology & Motility.2018;[Epub] CrossRef
Canadian packaged gluten-free foods are less nutritious than their regular gluten-containing counterparts
Jennifer A. Jamieson, Mary Weir, Laura Gougeon
PeerJ.2018; 6: e5875. CrossRef
Consensus document on exclusion diets in irritable bowel syndrome (IBS)
Francesc Casellas, Rosa Burgos, Ascensión Marcos, Javier Santos, Constanza Ciriza de los Ríos, Álvaro García Manzanares, Isabel Polanco, María Puy Portillo, Antonio Villarino, Beatriz Lema Marqués, María del Carmen Vázquez Alférez
Revista Española de Enfermedades Digestivas.2018;[Epub] CrossRef
Gluten-Free Diet and Its ‘Cousins’ in Irritable Bowel Syndrome
Anupam Rej, David Surendran Sanders
Nutrients.2018; 10(11): 1727. CrossRef
IRRITABLE BOWEL SYNDROME, FOOD INTOLERANCE AND NON- CELIAC GLUTEN SENSITIVITY. A NEW CLINICAL CHALLENGE
Rosa Leonôra Salerno SOARES
Arquivos de Gastroenterologia.2018; 55(4): 417. CrossRef
Randomized clinical trial: Effective gluten degradation by Aspergillus niger-derived enzyme in a complex meal setting
Julia König, Savanne Holster, Maaike J. Bruins, Robert J. Brummer
Scientific Reports.2017;[Epub] CrossRef
The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update
Carlo Catassi, Armin Alaedini, Christian Bojarski, Bruno Bonaz, Gerd Bouma, Antonio Carroccio, Gemma Castillejo, Laura De Magistris, Walburga Dieterich, Diana Di Liberto, Luca Elli, Alessio Fasano, Marios Hadjivassiliou, Matthew Kurien, Elena Lionetti, Ch
Nutrients.2017; 9(11): 1268. CrossRef
Irritable bowel syndrome and diet
Eirini Dimidi, Megan Rossi, Kevin Whelan
Current Opinion in Clinical Nutrition & Metabolic Care.2017; 20(6): 456. CrossRef
Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!
Anamaria Cozma-Petruţ, Felicia Loghin, Doina Miere, Dan Lucian Dumitraşcu
World Journal of Gastroenterology.2017; 23(21): 3771. CrossRef

8,879 View
112 Download
49 Web of Science
47 Crossref

Thirty-day mortality after percutaneous gastrostomy by endoscopic versus radiologic placement: a systematic review and meta-analysis: Joo Hyun Lim, Seung Ho Choi, Changhyun Lee, Ji Yeon Seo, Hae Yeon Kang, Jong In Yang, Su Jin Chung, Joo Sung Kim; Intest Res 2016;14(4):333-342. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.333

Abstract PDF PubReader

Background/Aims

A percutaneous gastrostomy can be placed either endoscopically (percutaneous endoscopic gastrostomy, PEG) or radiologically (radiologically-inserted gastrostomy, RIG). However, there is no consistent evidence of the safety and efficacy of PEG compared to RIG. Recently, 30-day mortality has become considered as the most important surrogate index for evaluating the safety and efficacy of percutaneous gastrostomy. The aim of this meta-analysis was to compare the 30-day mortality rates between PEG and RIG.

Methods

Major electronic databases (MEDLINE, Embase, Scopus, and Cochrane library) were queried for comparative studies on the two insertion techniques of gastrostomy among adults with swallowing disturbance. The primary outcome was the 30-day mortality rate after gastrostomy insertion. Forest and funnel plots were generated for outcomes using STATA version 14.0.

Results

Fifteen studies (n=2,183) met the inclusion criteria. PEG was associated with a lower risk of 30-day mortality after tube placement compared with RIG (odds ratio, 0.60; 95% confidence interval [CI], 0.38–0.94; P=0.026). The pooled prevalence of 30-day mortality of PEG was 5.5% (95% CI, 4.0%–6.9%) and that of RIG was 10.5% (95% CI, 6.8%–14.3%). No publication bias was noted.

Conclusions

The present meta-analysis demonstrated that PEG is associated with a lower probability of 30-day mortality compared to RIG, suggesting that PEG should be considered as the first choice for long-term enteral tube feeding. Further prospective randomized studies are needed to evaluate and compare the safety of these two different methods of gastrostomy.

Citations

Citations to this article as recorded by

Factors Predicting Major Complications and Mortality in Percutaneous Endoscopic Gastrostomy: 8 Years of Experience of a Tertiary Surgery Center
Murat Yildirim, Asim Kocabay, Bulent Koca, Ali Ihsan Saglam, Namik Ozkan
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2025;[Epub] CrossRef
Improving 30-day mortality after radiologically inserted gastrostomy tube from 2007 to 2019: A population-based study of 15,605 patients
Syed Shezal Hussain, Nosheen Umar, Umair Kamran, Benjamin Coupland, Fumi Varyani, Nigel Trudgill
Clinical Nutrition ESPEN.2025; 66: 381. CrossRef
S3-Leitlinie Heimenterale und heimparenterale Ernährung der Deutschen Gesellschaft für Ernährungsmedizin (DGEM)
Stephan C. Bischoff, Jann Arends, Christiane Decker-Baumann, Elisabeth Hütterer, Sebastian Koch, Stefan Mühlebach, Ingeborg Roetzer, Andrea Schneider, Claudia Seipt, Ralph Simanek, Zeno Stanga
Aktuelle Ernährungsmedizin.2024; 49(02): 73. CrossRef
Percutaneous radiologic gastrostomy versus percutaneous endoscopic gastrostomy for enteral feeding: A systematic review and meta‐analysis
Matheus Coelho Meine, Isabela Ho Tusato, Nathalia Hoffmeister, Gilmara Coelho Meine
Journal of Parenteral and Enteral Nutrition.2024; 48(6): 667. CrossRef
Direct Percutaneous Endoscopic Gastrostomy Versus Radiological Gastrostomy in Patients Unable to Undergo Transoral Endoscopic Pull Gastrostomy
Divyanshoo R. Kohli, Craig Smith, Omer Chaudhry, Madhav Desai, Dion DePaolis, Prateek Sharma
Digestive Diseases and Sciences.2023; 68(3): 852. CrossRef
Complications of Percutaneous Radiologic Gastrostomy Among Patients in a Tertiary Care Hospital in Riyadh, Saudi Arabia
Najla Alrasheed, Haneen S Khair, Renad M Aljohani, Noof M Alharbi, Nahlah N Alotaibi, Shahad F AlEdrees, Aamir Omair
Cureus.2023;[Epub] CrossRef
A retrospective study of outcomes and the validation of the Sheffield Gastrostomy Score in PEGs, RIGs and PIGs
Heather Parr, Lloyd Thomas, Prabhsimran Singh, Salma Mohammed, Khin Nu, John S. Kane, Fred Lee, Thomas Welbank, Andrew D. Hopper, Mark E. McAlindon, Elizabeth A. Williams, David S. Sanders
Scandinavian Journal of Gastroenterology.2023; 58(12): 1542. CrossRef
Endoscopic vs radiologic gastrostomy for enteral feeding: A systematic review and meta-analysis
Evellin Souza Valentim dos Santos, Guilherme Henrique Peixoto de Oliveira, Diogo Turiani Hourneaux de Moura, Bruno Salomão Hirsch, Roberto Paolo Trasolini, Wanderley Marques Bernardo, Eduardo Guimarães Hourneaux de Moura
World Journal of Meta-Analysis.2023; 11(6): 277. CrossRef
Outcomes of push and pull percutaneous endoscopic gastrostomy placements in 854 patients: A single‐center study
Hicham Bouchiba, Maarten A J M Jacobs, Gerd Bouma, Dewkoemar Ramsoekh
JGH Open.2022; 6(1): 57. CrossRef
Factors affecting late complications of percutaneous endoscopic gastrostomy tube replacement
Kasenee Tiankanon, Satimai Aniwan, Julalak Karuehardsuwan, Sumitra Wiangngoen, Rungsun Rerknimitr
Clinical Nutrition ESPEN.2022; 49: 378. CrossRef
The Outcomes of Nutritional Support Techniques in Patients with Gastrointestinal Cancers
Vlad-Alexandru Ionescu, Gina Gheorghe, Ruxandra Oprita, Madalina Stan-Ilie, Raluca-Ioana Dascalu, Ondin Zaharia, Viorel Jinga, Camelia Cristina Diaconu, Gabriel Constantinescu
Gastroenterology Insights.2022; 13(3): 245. CrossRef
Improving 30-day mortality after PEG tube placement in England from 2007 to 2019: a retrospective national cohort analysis of 87,862 patients
Umair Kamran, Pui Chi Lee, Ben Coupland, Abdullah Abbasi, Helen Steed, Sissi Ispoglou, Fumi Varyani, Nigel Trudgill
Gastrointestinal Endoscopy.2022; 96(6): 943. CrossRef
Outcomes following percutaneous endoscopic gastrostomy versus fluoroscopic procedures in the Medicare population
Samantha Maasarani, Syed I. Khalid, Chantal Creighton, Athena J. Manatis-Lornell, Aaron L. Wiegmann, Samantha L. Terranella, Nicholas J. Skertich, Laura DeCesare, Edie Y. Chan
Surgery Open Science.2021; 3: 2. CrossRef
Safety of endoscopic gastrostomy tube placement compared with radiologic or surgical gastrostomy: nationwide inpatient assessment
Divyanshoo R. Kohli, Kevin F. Kennedy, Madhav Desai, Prateek Sharma
Gastrointestinal Endoscopy.2021; 93(5): 1077. CrossRef
Laparoscopic vs open insertion of feeding gastrostomy tube in adults with head and neck cancers: A case‐matched comparative study
Balqees Omari, Huthaifa Asmer, Hani Al‐Najjar, Issa Mohamad, Omar Al‐Saraireh, Basil J. Ammori
International Journal of Clinical Practice.2021;[Epub] CrossRef
Percutaneous endoscopic gastrostomy
Xudong Liu, Zhengqiang Yang, Shun He, Guiqi Wang
International Journal of Gastrointestinal Intervention.2021; 10(2): 42. CrossRef
Scheduled percutaneous endoscopic gastrostomy tube replacement did not reduce PEG-related complications
Wisam Sbeit, Anas Kadah, Amir Shahin, Samer Shbat, Moeen Sbeit, Tawfik Khoury
Scandinavian Journal of Gastroenterology.2021; 56(11): 1386. CrossRef
Comparative Safety of Endoscopic vs Radiological Gastrostomy Tube Placement: Outcomes From a Large, Nationwide Veterans Affairs Database
Divyanshoo R. Kohli, Kevin F. Kennedy, Madhav Desai, Prateek Sharma
American Journal of Gastroenterology.2021; 116(12): 2367. CrossRef
ESPEN guideline on home enteral nutrition
Stephan C. Bischoff, Peter Austin, Kurt Boeykens, Michael Chourdakis, Cristina Cuerda, Cora Jonkers-Schuitema, Marek Lichota, Ibolya Nyulasi, Stéphane M. Schneider, Zeno Stanga, Loris Pironi
Clinical Nutrition.2020; 39(1): 5. CrossRef
Technical success rate and safety of radiologically inserted gastrostomy versus percutaneous endoscopic gastrostomy in motor neuron disease patients undergoing: A systematic review and meta-analysis
Tian-wen Yuan, Yang He, Sai-bo Wang, Peng Kong, Jun Cao
Journal of the Neurological Sciences.2020; 410: 116622. CrossRef
Predictors for 30-day mortality and complications following radiologically inserted gastrostomies: a single centre, large cohort review
J. Delf, S. Jepson, S. Ramachandran, M. Elabassy, B. Morgan, R. Kenningham, J.H. Mullineux, J.A. Stephenson
Clinical Radiology.2020; 75(5): 375. CrossRef
Gastropexy can be as safe as conventional percutaneous endoscopic gastrostomy (PEG), and biomarkers do not predict short-term or long-term outcomes: a 7-year follow-up audit
Ross J Porter, Alastair W McKinlay, Emma L Metcalfe
Frontline Gastroenterology.2020; 11(5): 364. CrossRef
Early versus Delayed Feeding after Percutaneous Endoscopic Gastrostomy Placement in Children: A Meta-Analysis
Jun Watanabe, Kazuhiko Kotani
Children.2020; 7(9): 124. CrossRef
Reducing 30-day post gastrostomy insertion mortality with a feeding issues multidisciplinary team meeting
A. Bond, T. Conley, J. Fiske, V. Raymond, A. Young, P. Collins, M. Dibb, P.J. Smith
Clinical Nutrition ESPEN.2020; 40: 282. CrossRef
Nutritional Support of Cancer Patients without Oral Feeding: How to Select the Most Effective Technique?
Gonçalo Nunes, Jorge Fonseca, Ana Teresa Barata, Mário Dinis-Ribeiro, Pedro Pimentel-Nunes
GE - Portuguese Journal of Gastroenterology.2020; 27(3): 172. CrossRef
Retrospective comparison of outcomes and associated complications between large bore radiologically inserted gastrostomy tube types
David J. Tischfield, Gregory J. Nadolski, Stephen J. Hunt, Maxim Itkin, Richard D. Shlansky-Goldberg, Terence P. Gade
Abdominal Radiology.2019; 44(1): 318. CrossRef
Percutaneous endoscopic gastrostomy for enteral nutrition: a 5-year clinical experience with 324 patients
Ezekiel W. Toh Yoon, Kaori Yoneda, Kazuki Nishihara
Minerva Gastroenterologica e Dietologica.2019;[Epub] CrossRef
Simple Bedside Predictors of Survival after Percutaneous Gastrostomy Tube Insertion
Wisam Sbeit, Anas Kadah, Amir Mari, Mahmud Mahamid, Tawfik Khoury
Canadian Journal of Gastroenterology and Hepatology.2019; 2019: 1. CrossRef
Risk factors for complications and mortality of percutaneous endoscopic gastrostomy insertion
Gyu Young Pih, Hee Kyong Na, Ji Yong Ahn, Kee Wook Jung, Do Hoon Kim, Jeong Hoon Lee, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung
BMC Gastroenterology.2018;[Epub] CrossRef
A Systematic Review and Meta-Analysis on Outcomes and Complications of Percutaneous Endoscopic Versus Radiologic Gastrostomy for Enteral Feeding
Denise Strijbos, Daniel Keszthelyi, Roel M.M. Bogie, Lennard P.L. Gilissen, Martin Lacko, Janneke G.J. Hoeijmakers, Christiaan van der Leij, Rogier de Ridder, Michiel W. de Haan, Ad A.M. Masclee
Journal of Clinical Gastroenterology.2018; 52(9): 753. CrossRef
Percutaneous Endoscopic Transgastric Jejunostomy (PEG‐J) Tube Placement for Levodopa‐Carbidopa Intrajejunal Gel Therapy in the Interventional Radiology Suite: A Long‐term Follow‐up
Maria Valeria Saddi, Marianna Sarchioto, Giulia Serra, Daniela Murgia, Valeria Ricchi, Marta Melis, Roberta Arca, Pierpaolo Carreras, Loredana Sitzia, Sandro Zedda, Giovanni Dui, Rosario Rossi, Anna Ticca, Maurizio Melis, Giovanni Cossu
Movement Disorders Clinical Practice.2018; 5(2): 191. CrossRef
Percutaneous Radiologically-Guided Gastrostomy (PRG): Safety, Efficacy and Trends in a Single Institution
Gerard ZX Low, Chow Wei Too, Yen Yeong Poh, Richard HG Lo, Bien Soo Tan, Apoorva Gogna, Farah Gillan Irani, Kiang Hiong Tay
Annals of the Academy of Medicine, Singapore.2018; 47(11): 494. CrossRef

7,339 View
82 Download
37 Web of Science
32 Crossref

Surgical management of inflammatory bowel disease in China: a systematic review of two decades: Qiao Yu, Ren Mao, Lei Lian, Siew chien Ng, Shenghong Zhang, Zhihui Chen, Yanyan Zhang, Yun Qiu, Baili Chen, Yao He, Zhirong Zeng, Shomron Ben-Horin, Xinming Song, Minhu Chen; Intest Res 2016;14(4):322-332. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.322

Abstract PDF Supplementary Material PubReader

Background/Aims

The past decades have seen increasing incidence and prevalence of inflammatory bowel disease (IBD) in China. This article aimed to summarize the current status and characteristics of surgical management for IBD in China.

Methods

We searched PubMed, Embase, and Chinese databases from January 1, 1990 to July 1, 2014 for all relevant studies on the surgical treatment IBD in China. Eligible studies with sufficient defined variables were further reviewed for primary and secondary outcome measures.

Results

A total of 74 studies comprising 2,007 subjects with Crohn's disease (CD) and 1,085 subjects with ulcerative colitis (UC) were included. The percentage of CD patients misdiagnosed before surgery, including misdiagnosis as appendicitis or UC, was 50.8%±30.9% (578/1,268). The overall postoperative complication rate was 22.3%±13.0% (267/1,501). For studies of UC, the overall postoperative complication rate was 22.2%±27.9% (176/725). In large research centers (n>50 surgical cases), the rates of emergency operations for CD (P=0.032) and in-hospital mortalities resulting from both CD and UC were much lower than those in smaller research centers (n≤50 surgical cases) (P=0.026 and P <0.001, respectively). Regarding the changes in CD and UC surgery over time, postoperative complications (P=0.045 for CD; P=0.020 for UC) and postoperative in-hospital mortality (P=0.0002 for CD; P=0.0160 for UC) both significantly improved after the year 2010.

Conclusions

The surgical management of IBD in China has improved over time. However, the rates of misdiagnosis and postoperative complications over the past two decades have remained high. Large research centers were found to have relatively better capacity for surgical management than the smaller ones. Higher quality prospective studies are needed in China.

Citations

Citations to this article as recorded by

Carbon monoxide produced by HO-1 upregulation is the main factor behind the abnormal motility seen in experimental ulcerative colitis in mice
Mengchao Zhao, Yaru Lei, Mengyuan Wang, Yixin Chen, Shaozhang Hou, Xinyuan Dai, Di Gao, Yudan Liu, Bruno Mazet, Lei Sha
American Journal of Physiology-Gastrointestinal and Liver Physiology.2025; 328(3): G311. CrossRef
Epidemiological research, burden, and clinical advances of inflammatory bowel disease in China
Hong Yang, Jiaming Qian
Chinese Medical Journal.2024; 137(9): 1009. CrossRef
Laparoscopic surgery contributes to a decrease in short-term complications in surgical ulcerative colitis patients during 2008–2017: a multicenter retrospective study in China
Zerong Cai, Xiaosheng He, Jianfeng Gong, Peng Du, Wenjian Meng, Wei Zhou, Jinbo Jiang, Bin Wu, Weitang Yuan, Qi Xue, Lianwen Yuan, Jinhai Wang, Jiandong Tai, Jie Liang, Weiming Zhu, Ping Lan, Xiaojian Wu
Intestinal Research.2023; 21(2): 235. CrossRef
Differences in inflammatory bowel diseases between East and West: a Chinese perspective
Guanglin Cui, Junling Li, Hanzhe Liu, Jann-Birger Laugsand, Zhanju Liu
Journal of Public Health.2021; 29(1): 19. CrossRef
Diagnostic and Predictive Value of Immune-Related Genes in Crohn’s Disease
Bing Yu, Yi-xin Yin, Yan-ping Tang, Kang-lai Wei, Zhi-gang Pan, Ke-Zhi Li, Xian-wen Guo, Bang-li Hu
Frontiers in Immunology.2021;[Epub] CrossRef
Role of a multidisciplinary team (MDT) in the diagnosis, treatment, and outcomes of inflammatory bowel disease: a single Chinese center's experience
Qiang Wu, Xuehong Wang, Feng Wu, Dehong Peng, Guotao Wu, Lichao Yang, Lianwen Yuan
BioScience Trends.2021; 15(3): 171. CrossRef
MANAGEMENT OF ILEOCECAL CROHN’S DISEASE DURING SURGICAL TREATMENT FOR ACUTE APPENDICITIS: A SYSTEMATIC REVIEW
Abel Botelho QUARESMA, Eron Fabio MIRANDA, Paulo Gustavo KOTZE
Arquivos de Gastroenterologia.2021; 58(4): 560. CrossRef
Risk factors and long-term outcome of disease extent progression in Asian patients with ulcerative colitis: a retrospective cohort study
Yun Qiu, Baili Chen, Yufei Li, Shanshan Xiong, Shenghong Zhang, Yao He, Zhirong Zeng, Shomron Ben-Horin, Minhu Chen, Ren Mao
BMC Gastroenterology.2019;[Epub] CrossRef
Initial medical and surgical management of inflammatory bowel disease in the biologic era: A comparison between the United States and China
Sanskriti Varma, Jun Hu, Ambar Mehta, Yiran Song, Angela Park, Min Zhi, Susan Hutfless
JGH Open.2019; 3(3): 234. CrossRef
Can molecular stratification improve the treatment of inflammatory bowel disease?
Claire Wang, Hannah M. Baer, Daniel R. Gaya, Robert J.B. Nibbs, Simon Milling
Pharmacological Research.2019; 148: 104442. CrossRef
Intrarectally administered polaprezinc attenuates the development of dextran sodium sulfate‑induced ulcerative colitis in mice
Zhaoyang Liu, Wenbo Xie, Mingru Li, Jing Liu, Xiao Liang, Tao Li
Experimental and Therapeutic Medicine.2019;[Epub] CrossRef
Changing treatment paradigms for the management of inflammatory bowel disease
Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
The Korean Journal of Internal Medicine.2018; 33(1): 28. CrossRef
Is Adsorptive Granulocyte and Monocyte Apheresis Effective as an Alternative Treatment Option in Patients with Ulcerative Colitis?
Seong Ran Jeon
Gut and Liver.2017; 11(2): 171. CrossRef

6,942 View
75 Download
13 Web of Science
13 Crossref

Narrow-band imaging with magnifying endoscopy for Peyer's patches is useful in predicting the recurrence of remissive patients with ulcerative colitis: Satoshi Hiyama, Hideki Iijima, Syoichiro Kawai, Akira Mukai, Eri Shiraishi, Shuko Iwatani, Toshio Yamaguchi, Manabu Araki, Yoshito Hayashi, Shinichiro Shinzaki, Tsunekazu Mizushima, Masahiko Tsujii, Tetsuo Takehara; Intest Res 2016;14(4):314-321. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.314

Abstract PDF Supplementary Material PubReader

Background/Aims

Peyer's patches (PPs) are aggregates of lymphoid follicles that are mainly located in the distal ileum; they play a major role in mucosal immunity. We recently reported that patients with ulcerative colitis (UC) have alterations in PPs that can be detected using narrow-band imaging with magnifying endoscopy (NBI-ME). However, the usefulness of NBI-ME in UC treatment as a whole is still unknown.

Methods

We collected NBI-ME images of PPs from 67 UC patients who had undergone ileocolonoscopy. We evaluated changes in the villi using the "villi index," which is based on three categories: irregular formation, hyperemia, and altered vascular network pattern. The patients were divided into two groups on the basis of villi index: low (L)- and high (H)-types. We then determined the correlation between morphological alteration of the PPs and various clinical characteristics. In 52 patients who were in clinical remission, we also analyzed the correlation between NBI-ME findings of PPs and clinical recurrence.

Results

The time to clinical recurrence was significantly shorter in remissive UC patients with H-type PPs than in those with L-type PPs (P<0.01). Moreover, PP alterations were not correlated with age, sex, disease duration, clinical activity, endoscopic score, or extent of disease involvement. Multivariate analysis revealed that the existence of H-type PPs was an independent risk factor for clinical recurrence (hazard ratio, 3.3; P<0.01).

Conclusions

UC patients with morphological alterations in PPs were at high risk of clinical relapse. Therefore, to predict the clinical course of UC, it may be useful to evaluate NBI-ME images of PPs.

Citations

Citations to this article as recorded by

Possible Role of Image-Enhanced Endoscopy in the Evaluation of Mucosal Healing of Ulcerative Colitis
Minoru Matsuura, Daisuke Saito, Jun Miyoshi, Tadakazu Hisamatsu
Digestion.2023; 104(1): 42. CrossRef
Endoscopic alterations in Peyer's patches in patients with ulcerative colitis: A prospective, multicenter study
Satoshi Hiyama, Hideki Iijima, Yuko Sakakibara, Takuya Yamada, Akira Mukai, Yuriko Otake, Toshio Yamaguchi, Manabu Araki, Shoichiro Kawai, Yoshiki Tsujii, Takahiro Inoue, Yoshito Hayashi, Shinichiro Shinzaki, Tetsuo Takehara
Journal of Gastroenterology and Hepatology.2020; 35(7): 1143. CrossRef
Can narrow-band imaging of Peyer's patches predict the recurrence of ulcerative colitis?
Yoon Jae Kim
Intestinal Research.2016; 14(4): 295. CrossRef

7,032 View
73 Download
3 Web of Science
3 Crossref

Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease: Hui Won Jang, Hyun Sook Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon; Intest Res 2016;14(4):305-313. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.305

Abstract PDF PubReader

Background/Aims

Several studies have found that the measurement of fecal calprotectin is useful for the early diagnosis of inflammatory bowel disease (IBD). We compared the effectiveness of three different fecal calprotectin kits for initial diagnosis in patients with suspected IBD.

Methods

We enrolled 31 patients with IBD (18 Crohn's disease [CD], 11 ulcerative colitis [UC], and two intestinal Behçet's disease), five with irritable bowel syndrome (IBS), and five with other colitis (four infectious colitis and one intestinal tuberculosis). Diagnosis was based on clinical, laboratory, and endoscopic examinations. Fecal samples were obtained at the first diagnosis and calprotectin levels were measured using three different kits (Quantum Blue® Calprotectin, EliA™ Calprotectin, and RIDASCREEN® Calprotectin).

Results

The overall accuracy for differentiating IBD from IBS or other colitis was 94% and 91%, respectively, for Quantum Blue® (cutoff, 50 µg/g); 92% and 89%, respectively, for EliA™ (cutoff, 50 µg/g); and 82% and 76%, respectively, for RIDASCREEN® (cutoff, 50 µg/g). In patients with CD, the results of Quantum Blue® Calprotectin and EliA™ Calprotectin correlated significantly with levels of the Crohn's disease activity index (Spearman's rank correlation coefficient, r=0.66 and r=0.49, respectively). In patients with UC, the results of EliA™ Calprotectin correlated significantly with the Mayo score (r=0.70).

Conclusions

Fecal calprotectin measurement is useful for the identification of IBD. The overall accuracies of the three fecal calprotectin kits are comparable.

Citations

Citations to this article as recorded by

Network pharmacology analysis and animal experiment validation of inflammation inhibition by Swertiamarin in treating Ulcerative colitis
Tang Jiafeng, Wang Lijuan, Wei Lan, You Yiqing, Yang Shiyu, Zeng Tao, Dang Tingting, Sun Haoli, Li Xiaoshan, Zhang Yan
Naunyn-Schmiedeberg's Archives of Pharmacology.2025;[Epub] CrossRef
Values of serum intestinal fatty acid-binding protein, fecal calprotectin, and fecal human β-defensin 2 for predicting necrotizing enterocolitis
Sujia Liu, Yongle Liu, Shuhua Lai, Yingling Xie, Wenlong Xiu, Changyi Yang
BMC Pediatrics.2024;[Epub] CrossRef
Multimodal Ultrasound Technology Combined with Fecal Calprotectin Assessment in Clinical Studies of Inflammatory Bowel Disease
泊辛陈
Advances in Clinical Medicine.2024; 14(07): 1110. CrossRef
The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park
Intestinal Research.2021; 19(1): 62. CrossRef
The utility of faecal and urine biomarkers for small bowel diseases
M.S. Ismail, Serhiy Semenov, Deirdre McNamara
Current Opinion in Gastroenterology.2021; 37(3): 284. CrossRef
A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease
Jong-Mi Lee, Joo Hee Jang, Ji Hyeong Ryu, Jaeeun Yoo, Bo-In Lee, Seung-Jun Kim, Eun-Jee Oh, Hsu-Heng Yen
PLOS ONE.2021; 16(8): e0255974. CrossRef
Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis
Ho Min Yong, Sung-Jo Park, Seong Ran Jeon, Heesu Park, Hyun Gun Kim, Tae Hee Lee, Junseok Park, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Hyeon Jeong Goong, Suyeon Park
Medicine.2021; 100(34): e27065. CrossRef
Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn’s Disease Based on Serum Levels of Proteins
Geert D’Haens, Orlaith Kelly, Robert Battat, Mark S. Silverberg, David Laharie, Edouard Louis, Edoardo Savarino, Giorgia Bodini, Andres Yarur, Brigid S. Boland, Waqqas Afif, Xiao-jun Li, Michael Hale, Jessica Ho, Venkateswarlu Kondragunta, Benjamin Huang,
Gastroenterology.2020; 158(3): 515. CrossRef
Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations
Emilio J. Laserna-Mendieta, Alfredo J. Lucendo
Clinical Chemistry and Laboratory Medicine (CCLM).2019; 57(9): 1295. CrossRef
Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease?
Christopher Ma, Robert Battat, Claire E. Parker, Reena Khanna, Vipul Jairath, Brian Gordon Feagan
Expert Review of Gastroenterology & Hepatology.2019; 13(4): 319. CrossRef
Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases
Parambir S. Dulai, Laurent Peyrin-Biroulet, Silvio Danese, Bruce E. Sands, Axel Dignass, Dan Turner, Gerassimos Mantzaris, Juergen Schölmerich, Jean-Yves Mary, Walter Reinisch, William J. Sandborn
Gastroenterology.2019; 157(4): 1032. CrossRef
Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy
Karoline Freeman, Brian H Willis, Hannah Fraser, Sian Taylor-Phillips, Aileen Clarke
BMJ Open.2019; 9(3): e027428. CrossRef
Extraction, isolation, and concentration of calprotectin antigen (S100A8/S100A9) from granulocytes
Tom Nilsen, Siri Helen Haugen, Anders Larsson
Health Science Reports.2018;[Epub] CrossRef
Fecal Immunochemical Test and Fecal Calprotectin Measurement Are Noninvasive Monitoring Tools for Predicting Endoscopic Activity in Patients with Ulcerative Colitis
Ji Young Chang, Jae Hee Cheon
Gut and Liver.2018; 12(2): 117. CrossRef
Fecal calprotectin is not superior to serum C-reactive protein or the Harvey–Bradshaw index in predicting postoperative endoscopic recurrence in Crohn’s disease
Cristina Verdejo, Daniel Hervías, Óscar Roncero, Ángel Arias, Abdelmouneim Bouhmidi, Rufo Lorente, Irina Salueña, Alfredo J. Lucendo
European Journal of Gastroenterology & Hepatology.2018; 30(12): 1521. CrossRef
Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring
Shu-Chen Wei, Chien-Chih Tung, Meng-Tzu Weng, Jau-Min Wong
Intestinal Research.2018; 16(4): 546. CrossRef
Serum Adipocytokine Levels as Surrogate Markers for Disease Activity of Crohn’s Disease
Su Hwan Kim, Seung Hyeon Jang, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, You Sun Kim, Dong Soo Han, Joo Sung Kim
The American Journal of the Medical Sciences.2017; 353(5): 439. CrossRef
Fecal biomarkers in inflammatory bowel disease: how, when and why?
Paula Ministro, Diana Martins
Expert Review of Gastroenterology & Hepatology.2017; 11(4): 317. CrossRef
Could fecal calprotectin enter mainstream use for diagnosing and monitoring inflammatory bowel disease?
Shu Chen Wei
Intestinal Research.2016; 14(4): 293. CrossRef

8,468 View
76 Download
18 Web of Science
19 Crossref

Characteristics and outcomes of endoscopically resected colorectal cancers that arose from sessile serrated adenomas and traditional serrated adenomas: Ji Yeon Seo, Seung Ho Choi, Jaeyoung Chun, Changhyun Lee, Ji Min Choi, Eun Hyo Jin, Sung Wook Hwang, Jong Pil Im, Sang Gyun Kim, Joo Sung Kim; Intest Res 2016;14(3):270-279. Published online June 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.3.270

Abstract PDF PubReader ePub

Background/Aims

The efficacy and safety of endoscopic resection of colorectal cancer derived from sessile serrated adenomas or traditional serrated adenomas are still unknown. The aims of this study were to verify the characteristics and outcomes of endoscopically resected early colorectal cancers developed from serrated polyps.

Methods

Among patients who received endoscopic resection of early colorectal cancers from 2008 to 2011, cancers with documented pre-existing lesions were included. They were classified as adenoma, sessile serrated adenoma, or traditional serrated adenoma according to the baseline lesions. Clinical characteristics, pathologic diagnosis, and outcomes were reviewed.

Results

Overall, 208 colorectal cancers detected from 198 patients were included: 198 with adenoma, five with sessile serrated adenoma, and five with traditional serrated adenoma. The sessile serrated adenoma group had a higher prevalence of high-grade dysplasia (40.0% vs. 25.8%, P<0.001) than the adenoma group. During follow-up, local recurrence did not occur after endoscopic resection of early colorectal cancers developed from serrated polyps. In contrast, two cases of metachronous recurrence were detected within a short follow-up period.

Conclusions

Cautious observation and early endoscopic resection are recommended when colorectal cancer from serrated polyp is suspected. Colorectal cancers from serrated polyp can be treated successfully with endoscopy.

Citations

Citations to this article as recorded by

Small sessile serrated polyps might not be at a higher risk for future advanced neoplasia than low-risk adenomas or polyp-free groups
Eun Hyo Jin, Ji Yeon Seo, Jung Ho Bae, Jooyoung Lee, Ji Min Choi, Yoo Min Han, Joo Hyun Lim
Scandinavian Journal of Gastroenterology.2022; 57(1): 99. CrossRef
The incidence and risk factors of sessile serrated adenomas in left side colon cancer patients after curative surgery
Myung Hee Kim, Hee Seok Moon, In Sun Kwon, Ju Seok Kim, Sun Hyung Kang, Jae Kyu Sung, Eaum Seok Lee, Seok Hyun Kim, Byung Seok Lee, Hyun Yong Jeong
Medicine.2020; 99(29): e20799. CrossRef
Improved Real-Time Optical Diagnosis of Colorectal Polyps Following a Comprehensive Training Program
Jung Ho Bae, Changhyun Lee, Hae Yeon Kang, Min-Sun Kwak, Eun Young Doo, Ji Yeon Seo, Ji Hyun Song, Sun Young Yang, Jong In Yang, Seon Hee Lim, Jeong Yoon Yim, Joo Hyun Lim, Goh Eun Chung, Su Jin Chung, Eun Hyo Jin, Boram Park, Joo Sung Kim
Clinical Gastroenterology and Hepatology.2019; 17(12): 2479. CrossRef
Clinical outcomes of surveillance colonoscopy for patients with sessile serrated adenoma
Sung Jae Park, Hyuk Yoon, In Sub Jung, Cheol Min Shin, Young Soo Park, Na Young Kim, Dong Ho Lee
Intestinal Research.2018; 16(1): 134. CrossRef
Surveillance colonoscopy in patients with sessile serrated adenoma
Ji Hyung Nam, Hyoun Woo Kang
Intestinal Research.2018; 16(3): 502. CrossRef
Identification of risk factors for sessile and traditional serrated adenomas of the colon by using big data analysis
Jeung Hui Pyo, Sang Yun Ha, Sung Noh Hong, Dong Kyung Chang, Hee Jung Son, Kyoung‐Mee Kim, Hyeseung Kim, Kyunga Kim, Jee Eun Kim, Yoon‐Ho Choi, Young‐Ho Kim
Journal of Gastroenterology and Hepatology.2018; 33(5): 1039. CrossRef
Endoscopic Resection of Cecal Polyps Involving the Appendiceal Orifice: A KASID Multicenter Study
Eun Mi Song, Hyo-Joon Yang, Hyun Jung Lee, Hyun Seok Lee, Jae Myung Cha, Hyun Gun Kim, Yunho Jung, Chang Mo Moon, Byung Chang Kim, Jeong-Sik Byeon
Digestive Diseases and Sciences.2017; 62(11): 3138. CrossRef
Is colorectal cancer screening necessary before 50 years of age?
Yoon Suk Jung
Intestinal Research.2017; 15(4): 550. CrossRef
Derivation and validation of a risk scoring model to predict advanced colorectal neoplasm in adults of all ages
Hyo‐Joon Yang, Sungkyoung Choi, Soo‐Kyung Park, Yoon Suk Jung, Kyu Yong Choi, Taesung Park, Ji Yeon Kim, Dong Il Park
Journal of Gastroenterology and Hepatology.2017; 32(7): 1328. CrossRef
Risk factors of missed colorectal lesions after colonoscopy
Jeonghun Lee, Sung Won Park, You Sun Kim, Kyung Jin Lee, Hyun Sung, Pil Hun Song, Won Jae Yoon, Jeong Seop Moon
Medicine.2017; 96(27): e7468. CrossRef

6,659 View
57 Download
11 Web of Science
10 Crossref

Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients with high risk of colorectal cancer: Sawan Bopanna, Maitreyee Roy, Prasenjit Das, S Dattagupta, V Sreenivas, V Pratap Mouli, Saurabh Kedia, Rajan Dhingra, Rajesh Pradhan, N Suraj Kumar, Dawesh P Yadav, Govind Makharia, Vineet Ahuja; Intest Res 2016;14(3):264-269. Published online June 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.3.264

Abstract PDF PubReader ePub

Background/Aims

Recent data suggest that the incidence of ulcerative colitis (UC) related colorectal cancer (CRC) in India is similar to that of West. The optimum method for surveillance is still a debate. Surveillance with random biopsies has been the standard of care, but is a tedious process. We therefore undertook this study to assess the yield of random biopsy in dysplasia surveillance.

Methods

Between March 2014 and July 2015, patients of UC attending the Inflammatory Bowel Disease clinic at the All India Institute of Medical Sciences with high risk factors for CRC like duration of disease >15 years and pancolitis, family history of CRC, primary sclerosing cholangitis underwent surveillance colonoscopy for dysplasia. Four quadrant random biopsies at 10 cm intervals were taken (33 biopsies). Two pathologists examined specimens for dysplasia, and the yield of dysplasia was calculated.

Results

Twenty-eight patients were included. Twenty-six of these had pancolitis with a duration of disease greater than 15 years, and two patients had associated primary sclerosing cholangis. No patient had a family history of CRC. The mean age at onset of disease was 28.89±8.73 years and the duration of disease was 19.00±8.78 years. Eighteen patients (64.28%) were males. A total of 924 biopsies were taken. None of the biopsies revealed any evidence of dysplasia, and 7/924 (0.7%) were indefinite for dysplasia.

Conclusions

Random biopsy for surveillance in longstanding extensive colitis has a low yield for dysplasia and does not suffice for screening. Newer techniques such as chromoendoscopy-guided biopsies need greater adoption.

Citations

Citations to this article as recorded by

Interlukin-23 inhibitors as an induction and maintenance therapy for moderate to severe ulcerative colitis: a systematic review and meta‑analysis of randomized controlled trials
Omar Saab, Hasan Al-Obaidi, Marwah Algodi, Asma Algodi, Yasir Rashid, Alhareth Al-Sagban, Hayder Alamily, Nooraldin Merza, Layth Alzubaidy, Andrew DuPont
Inflammation Research.2025;[Epub] CrossRef
Etrolizumab as an induction and maintenance therapy for ulcerative colitis: A systematic review and meta‐analysis of randomized controlled trials
Othman Saleh, Mohamed T. Abuelazm, Islam Mohamed, Alaa Ramadan, Mohammad Assaf, Ahmad Alzoubi, Majd M. AlBarakat, Basel Abdelazeem
JGH Open.2024;[Epub] CrossRef
Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India
Arshdeep Singh, Vandana Midha, Vikram Narang, Saurabh Kedia, Ramit Mahajan, Pavan Dhoble, Bhavjeet Kaur Kahlon, Ashvin Singh Dhaliwal, Ashish Tripathi, Shivam Kalra, Narender Pal Jain, Namita Bansal, Rupa Banerjee, Devendra Desai, Usha Dutta, Vineet Ahuja
Intestinal Research.2023; 21(4): 452. CrossRef
Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question
Roberto Gabbiadini, Ferdinando D’Amico, Alessandro De Marco, Maria Terrin, Alessandra Zilli, Federica Furfaro, Mariangela Allocca, Gionata Fiorino, Silvio Danese
Journal of Clinical Medicine.2022; 11(3): 509. CrossRef
Endoscopic Surveillance in Inflammatory Bowel Diseases: Selecting a Suitable Technology
Arianna Dal Buono, Roberto Gabbiadini, Federica Furfaro, Marjorie Argollo, Thaís Viana Tavares Trigo, Alessandro Repici, Giulia Roda
Frontiers in Medicine.2022;[Epub] CrossRef
Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes
Federica Gaiani, Federica Marchesi, Francesca Negri, Luana Greco, Alberto Malesci, Gian Luigi de’Angelis, Luigi Laghi
International Journal of Molecular Sciences.2021; 22(10): 5246. CrossRef
Histopathological study of endoscopic biopsies of large intestine
Manjiri N Karandikar, Purva Kulkarni, Smita Mulay, R C Nimbergi, N S Mani
Indian Journal of Pathology and Oncology.2021; 8(3): 340. CrossRef
Is histological remission of ulcerative colitis achievable?
Oleg V. Knyazev, Anna V. Kagramanova, Sergei G. Khomeriki, Asfold I. Parfenov
Terapevticheskii arkhiv.2021; 93(8): 975. CrossRef
A Systematic Review and Meta-Analysis on the Association between Inflammatory Bowel Disease Family History and Colorectal Cancer
Hadis Najafimehr, Hamid Asadzadeh Aghdaei, Mohamad Amin Pourhoseingholi, Hamid Mohaghegh Shalmani, Amir Vahedian-Azimi, Matthew Kroh, Mohammad Reza Zali, Amirhossein Sahebkar, Muhammad Naeem
Gastroenterology Research and Practice.2021; 2021: 1. CrossRef
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi
Intestinal Research.2021; 19(4): 419. CrossRef
Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy
Oleg V. Knyazev, Sergey G. Khomeriki, Аnna V. Kagramanova, Albina A. Lishchinskaya, Olga A. Smirnova, Karina K. Noskova, Asfold I. Parfenov
Terapevticheskii arkhiv.2021; 93(12): 1435. CrossRef
Discovery and Validation of Methylation Biomarkers for Ulcerative Colitis Associated Neoplasia
Andrew D Beggs, Jonathan James, Germaine Caldwell, Toby Prout, Mark P Dilworth, Phillipe Taniere, Tariq Iqbal, Dion G Morton, Glenn Matthews
Inflammatory Bowel Diseases.2018; 24(7): 1503. CrossRef
Can histologic remission be a better prognostic factor and therapeutic target beyond endoscopic mucosal healing in patients with ulcerative colitis?
Hyo Jun Ahn, Sang-Bum Kang
Intestinal Research.2018; 16(1): 1. CrossRef
The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment
Louise C. Connell, José Mauricio Mota, Maria Ignez Braghiroli, Paulo M. Hoff
Current Treatment Options in Oncology.2017;[Epub] CrossRef
Screening strategy for colorectal cancer according to risk
Dong Soo Han
Journal of the Korean Medical Association.2017; 60(11): 893. CrossRef

6,715 View
59 Download
15 Web of Science
15 Crossref

Change in the diagnosis of inflammatory bowel disease: a hospital-based cohort study from Korea: Ho-Su Lee, Jaewon Choe, Hyo Jeong Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Yong Sik Yoon, Chang Sik Yu, Jin-Ho Kim, Suk-Kyun Yang; Intest Res 2016;14(3):258-263. Published online June 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.3.258

Abstract PDF PubReader ePub

Background/Aims

Accurately diagnosing inflammatory bowel disease (IBD) remains a challenge, but is crucial for providing proper management for affected patients. The aim of the present study was to evaluate the frequency of change in diagnosis in Korean patients who were referred to our institution with a diagnosis of IBD.

Methods

We enrolled 1,444 patients diagnosed with ulcerative colitis (UC) and 1,452 diagnosed with Crohn's disease (CD), who had been referred to the Asan Medical Center between January 2010 and December 2014. These patients were assessed and subsequently classified as having UC, CD, indeterminate colitis, possible IBD, or non-IBD.

Results

During a median follow-up of 15.9 months, 400 of the 2,896 patients (13.8%) analyzed in this study experienced a change in diagnosis. A change in diagnosis from UC to CD, or vice-versa, was made in 24 of 1,444 patients (1.7%) and 23 of 1,452 patients (1.6%), respectively. A change to a non-IBD diagnosis was the most common modification; 7.5% (108 of 1444) and 12.7% (184 of 1452) of the patients with a referral diagnosis of UC and CD, respectively, were reclassified as having non-IBD. Among the 292 patients who were ultimately determined not to have IBD, 135 (55 UC and 80 CD cases) had received IBD-related medication.

Conclusions

There are diagnostic uncertainties and difficulties in relation to IBD. Therefore, precise assessment and systematic follow-up are essential in the management of this condition.

Citations

Citations to this article as recorded by

Diagnosis change in pediatric inflammatory bowel disease
Harold Duarte, Adrienne Stolfi, Courtney McCall, Shehzad Saeed, Kelly Sandberg
Journal of Pediatric Gastroenterology and Nutrition.2024; 78(3): 623. CrossRef
A Case Report and Literature Review of Rectosigmoid Crohn’s Disease: A Diagnostic Pitfall Ultimately Leading to Spontaneous Colonic Perforation
Muhammad Z Ali, Muhammad Usman Tariq, Muhammad Hasan Abid, Hamma Abdulaziz, Mohmmad AlAdwani, Arif Khurshid, Muhammad Rashid, Fawaz Al Thobaiti , Amjad Althagafi
Cureus.2023;[Epub] CrossRef
Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end-stage kidney failure: A case report
Guglielmo Albertini Petroni, Laura Francesca Pisani, Edoardo Borsotti, Maria Doria, Maria Laura Annunziata
SAGE Open Medical Case Reports.2023;[Epub] CrossRef
Thirty-year Trend in Inflammatory Bowel Disease on Jeju Island, South Korea
Jin Woo Kim, Hyun Joo Song, Sun-Jin Boo, Heung Up Kim, Ki Soo Kang, Soo-Young Na
The Korean Journal of Gastroenterology.2023; 81(6): 243. CrossRef
PD-1-positive cells contribute to the diagnosis of inflammatory bowel disease and can aid in predicting response to vedolizumab
Min Kyu Kim, Su In Jo, Sang-Yeob Kim, Hyun Lim, Ho Suk Kang, Sung‑Hoon Moon, Byong Duk Ye, Jae Seung Soh, Sung Wook Hwang
Scientific Reports.2023;[Epub] CrossRef
IBD barriers across the continents – East Asia
Joyce Wing Yan Mak, Agnes Hiu Yan Ho, Siew Chien Ng
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef
Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef
Systematic evaluation of the diagnostic approach of inflammatory bowel disease guidelines
Bing‐He Xiao, Xu‐Dong Ma, Jia‐Jun Lv, Ting Yang, Xin‐Jie Liu, Li‐Ya An, Yu‐Xing Qi, Ming‐Liang Lu, Yong‐Qing Duan, Da‐Li Sun
International Journal of Clinical Practice.2021;[Epub] CrossRef
Clinical characteristics and prognosis of patients with ulcerative colitis that shows rectal sparing at initial diagnosis
Yong-Sung Choi, Jong-Kyu Kim, Wan-Jung Kim
World Journal of Gastrointestinal Endoscopy.2021; 13(9): 407. CrossRef
Current status of inflammatory bowel diseases in Korea
Suk-Kyun Yang
Journal of the Korean Medical Association.2021; 64(9): 572. CrossRef
EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain
María Chaparro, Manuel Barreiro-de Acosta, José Manuel Benítez, José Luis Cabriada, María José Casanova, Daniel Ceballos, María Esteve, Hipólito Fernández, Daniel Ginard, Fernando Gomollón, Rufo Lorente, Pilar Nos, Sabino Riestra, Montserrat Rivero, Pilar
Therapeutic Advances in Gastroenterology.2019;[Epub] CrossRef
Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes
Lukasz S. Wylezinski, Jamieson D. Gray, Julia B. Polk, Andrew J. Harmata, Charles F. Spurlock
Journal of Clinical Medicine.2019; 8(4): 493. CrossRef
Impact of Cumulative Corticosteroid Dosage on Preventable Hospitalization among Taiwanese Patients with Ankylosing Spondylitis and Inflammatory Bowel Disease
Beth I. Wallace, Chelsea A. Harris, Lu Wang, Mochuan Liu, Jung-Sheng Chen, Chang-Fu Kuo, Kevin C. Chung
Journal of Clinical Medicine.2019; 8(5): 614. CrossRef
Perforated diverticulitis in the setting of ulcerative colitis: An unusual case report
M. Baimas-George, L. Cetrulo, A. Kao, K.R. Kasten
International Journal of Surgery Case Reports.2018; 49: 126. CrossRef
Assessment of factors associated with smoking cessation at diagnosis or during follow‐up of Crohn's disease
Eun Mi Song, Gwang‐Un Kim, Myeongsook Seo, Sung Wook Hwang, Sang Hyoung Park, Eunja Kwon, Ho‐Su Lee, Dong‐Hoon Yang, Kyung‐Jo Kim, Byong Duk Ye, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang
Journal of Gastroenterology and Hepatology.2018; 33(1): 180. CrossRef
Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011–2014: A Nationwide Population-Based Study
Yoon Suk Jung, Minkyung Han, Won Ho Kim, Sohee Park, Jae Hee Cheon
Digestive Diseases and Sciences.2017; 62(8): 2102. CrossRef
Human alpha defensin 5 is a candidate biomarker to delineate inflammatory bowel disease
Amanda D. Williams, Olga Y. Korolkova, Amos M. Sakwe, Timothy M. Geiger, Samuel D. James, Roberta L. Muldoon, Alan J. Herline, J. Shawn Goodwin, Michael G. Izban, Mary K. Washington, Duane T. Smoot, Billy R. Ballard, Maria Gazouli, Amosy E. M'Koma, Shree
PLOS ONE.2017; 12(8): e0179710. CrossRef
Clinical course of ulcerative colitis patients who develop acute pancreatitis
Jong Wook Kim, Sung Wook Hwang, Sang Hyoung Park, Tae Jun Song, Myung-Hwan Kim, Ho-Su Lee, Byong Duk Ye, Dong-Hoon Yang, Kyung-Jo Kim, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
World Journal of Gastroenterology.2017; 23(19): 3505. CrossRef
Overall and cause‐specific mortality in Korean patients with inflammatory bowel disease: A hospital‐based cohort study
Ho‐Su Lee, Jaewon Choe, Seon‐Ok Kim, Sun‐Ho Lee, Hyo Jeong Lee, Hyungil Seo, Gwang‐Un Kim, Myeongsook Seo, Eun Mi Song, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Kyung‐Jo Kim, Byong Duk Ye, Jeong‐Sik Byeon, Seung‐Jae Myung, Yong Sik Yoon, Chang S
Journal of Gastroenterology and Hepatology.2017; 32(4): 782. CrossRef
Endoscopic Diagnosis and Differentiation of Inflammatory Bowel Disease
Ji Min Lee, Kang-Moon Lee
Clinical Endoscopy.2016; 49(4): 370. CrossRef

5,880 View
75 Download
21 Web of Science
20 Crossref

A retrospective analysis of 20-year data of the surgical management of ulcerative colitis patients in Taiwan: a study of Taiwan Society of Inflammatory Bowel Disease: Chun-Chi Lin, Shu-Chen Wei, Been-Ren Lin, Wen-Sy Tsai, Jinn-Shiun Chen, Tzu-Chi Hsu, Wei-Chen Lin, Tien-Yu Huang, Te-Hsin Chao, Hung-Hsin Lin, Jau-Min Wong, Jen-Kou Lin; Intest Res 2016;14(3):248-257. Published online June 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.3.248

Abstract PDF PubReader ePub

Background/Aims

With the recent progress in medical treatment, surgery still plays a necessary and important role in treating ulcerative colitis (UC) patients. In this study, we analyzed the surgical results and outcomes of UC in Taiwan in the recent 20 years, via a multi-center study through the collaboration of Taiwan Society of IBD.

Methods

A retrospective analysis of surgery data of UC patients from January 1, 1995, through December 31, 2014, in 6 Taiwan major medical centers was conducted. The patients' demographic data, indications for surgery, and outcome details were recorded and analyzed.

Results

The data of 87 UC patients who received surgical treatment were recorded. The median post-operative follow-up duration was 51.1 months and ranged from 0.4 to 300 months. The mean age at UC diagnosis was 45.3±16.0 years and that at operation was 48.5±15.2 years. The 3 leading indications for surgical intervention were uncontrolled bleeding (16.1%), perforation (13.8%), and intractability (12.6%). In total, 27.6% of surgeries were performed in an emergency setting. Total or subtotal colectomy with rectal preservation (41.4%) was the most common operation. There were 6 mortalities, all due to sepsis. Emergency operation and low pre-operative albumin level were significantly associated with poor survival (P=0.013 and 0.034, respectively).

Conclusions

In the past 20 years, there was no significant change in the indications for surgery in UC patients. Emergency surgeries and low pre-operative albumin level were associated with poor survival. Therefore, an optimal timing of elective surgery for people with poorly controlled UC is paramount.

Citations

Citations to this article as recorded by

Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
Hsu-Heng Yen, Jia-Feng Wu, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin
Intestinal Research.2024; 22(3): 213. CrossRef
Minimally Invasive Surgical Approach to Toxic Colitis
Zhobin Moghadamyeghaneh, Murwarid Rahimi, Katherine Kopatsis, Anthony Paul Kopatsis, Anthony Kopatsis
The American Surgeon.2022; 88(7): 1411. CrossRef
Effectiveness and safety of acupuncture therapy for inflammatory bowel disease: a protocol of systematic review and meta-analysis
Yuan-Fang Zhou, Ning Sun, Shi-Rui Cheng, Xiao-Dong Deng, Xiang-Yin Ye, Zheng-Jie Li, Jun Zhou, Gui-Xing Xu, Yu-Zhu Qu, Liu-Yang Huang, Rui-Rui Sun, Fan-Rong Liang
BMJ Open.2021; 11(8): e045090. CrossRef
Recent Advance in the Management of Dysplasia in the Ulcerative Colitis
Dong-Hoon Yang
Journal of Digestive Cancer Reports.2021; 9(2): 50. CrossRef
Trends and risk factors of mortality analysis in patients with inflammatory bowel disease: a Taiwanese nationwide population-based study
Wei-Chen Lin, Meng-Tzu Weng, Chien-Chih Tung, Yuan-Ting Chang, Yew-Loong Leong, Yu-Ting Wang, Horng-Yuan Wang, Jau-Min Wong, Shu-Chen Wei
Journal of Translational Medicine.2019;[Epub] CrossRef
Variant Two-Stage Ileal Pouch-Anal Anastomosis: An Innovative and Effective Alternative to Standard Resection in Ulcerative Colitis
Jennifer Samples, Krista Evans, Nicole Chaumont, Paula Strassle, Timothy Sadiq, Mark Koruda
Journal of the American College of Surgeons.2017; 224(4): 557. CrossRef

5,565 View
50 Download
6 Web of Science
6 Crossref

Quality of care in inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2^nd Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul: Hye Kyung Song, Kang-Moon Lee, Sung-Ae Jung, Sung Noh Hong, Dong Soo Han, Suk-Kyun Yang; Intest Res 2016;14(3):240-247. Published online June 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.3.240

Abstract PDF PubReader ePub

Background/Aims

The quality of care in inflammatory bowel disease (IBD) has not been systematically estimated. The aim of this study was to investigate the current status of quality of IBD care in Asian countries.

Methods

A questionnaire-based survey was conducted between March 2014 and May 2014. The questionnaire was adopted from "An adult inflammatory bowel disease physician performance measure set" developed by the American Gastroenterological Association. If the respondent executed the performance measure in more than 70% of patients, the measure was regarded as well performed.

Results

A total of 353 medical doctors from Asia completed the survey (116 from Korea, 114 from China, 88 from Japan, 17 from Taiwan, 8 from Hong-Kong, 4 from India, 3 from Singapore, and 1 each from the Philippines, Malaysia and Indonesia). The delivery of performance measures, however, varied among countries. The documentation of IBD and tuberculosis screening before anti-tumor necrosis factor therapy were consistently performed well, while pneumococcal immunization and prophylaxis of venous thromboembolisms in hospitalized patients were performed less frequently in all countries. Physician awareness was positively associated with the delivery of performance measures. Variations were also noted in reasons for non-performance or low performance of quality measures, and the two primary reasons cited were consideration of the measure to be unimportant and lack of time.

Conclusions

The delivery of performance measures varies among physicians in Asian countries, and reflects variations in the quality of care among the countries. This variation should be recognized to improve the quality of care in Asian countries.

Citations

Citations to this article as recorded by

Incidence of Venous Thromboembolism in Asian Patients With Inflammatory Bowel Disease: A Systematic Review and Meta‐Analysis
Joo Hye Song, Sung Ryul Shim, Dae Sung Kim, Hoon Sup Koo, Kyu Chan Huh
Journal of Gastroenterology and Hepatology.2025; 40(4): 774. CrossRef
The Incidence and Predictive Factors of Thromboembolism During Hospitalizations for Inflammatory Bowel Disease Flare‐Ups: A Retrospective Cohort Study in Taiwan
Ming‐Jung Meng, Chen‐Shuan Chung, Chen‐Wang Chang, Yu‐Bin Pan, Chia‐Jung Kuo, Cheng‐Tang Chiu, Puo‐Hsien Le
Journal of Evaluation in Clinical Practice.2024;[Epub] CrossRef
Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im
Intestinal Research.2023; 21(3): 353. CrossRef
Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
Intestinal Research.2023; 21(3): 339. CrossRef
IBD barriers across the continents – East Asia
Joyce Wing Yan Mak, Agnes Hiu Yan Ho, Siew Chien Ng
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef
Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease: A Population-Based Nationwide Inception Cohort Study
Su Young Kim, Yeon Seo Cho, Hyun-Soo Kim, Jung Kuk Lee, Hee Man Kim, Hong Jun Park, Hyunil Kim, Jihoon Kim, Dae Ryong Kang
Gut and Liver.2022; 16(4): 555. CrossRef
Risk of venous thromboembolism in Asian patients with inflammatory bowel disease: a nationwide cohort study
Chan Mi Heo, Tae Jun Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Mi Yang, Seonwoo Kim, Young-Ho Kim
Scientific Reports.2021;[Epub] CrossRef
Incidence and risk factors for venous thrombosis among patients with inflammatory bowel disease in China: a multicenter retrospective study
Jing Liu, Xiang Gao, Ye Chen, Qiao Mei, Liangru Zhu, Jiaming Qian, Pinjin Hu, Qian Cao
Intestinal Research.2021; 19(3): 313. CrossRef
Anti-tumor Necrosis Factor Agents and Tuberculosis in Inflammatory Bowel Disease
Yunho Jung
The Korean Journal of Gastroenterology.2020; 75(1): 1. CrossRef
Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia
Rupa Banerjee, Partha Pal, Joyce Wing Yan Mak, Siew C Ng
The Lancet Gastroenterology & Hepatology.2020; 5(12): 1076. CrossRef
Quality of care in inflammatory bowel disease: actual health service experiences fall short of the standards
Antonina Mikocka‐Walus, Wayne Massuger, Simon R. Knowles, Gregory T. Moore, Stephanie Buckton, William Connell, Paul Pavli, Leanne Raven, Jane M. Andrews
Internal Medicine Journal.2020; 50(10): 1216. CrossRef
Improving the quality of care for inflammatory bowel disease
Byong Duk Ye, Simon Travis
Intestinal Research.2019; 17(1): 45. CrossRef
Should Asian inflammatory bowel disease patients need routine thromboprophylaxis?
Meng-Tzu Weng, Chien-Chih Tung, Jau-Min Wong, Shu-Chen Wei
Intestinal Research.2018; 16(2): 312. CrossRef
Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies
Lorant Gonczi, Zsuzsanna Kurti, Petra Anna Golovics, Barbara Dorottya Lovasz, Orsolya Menyhart, Anna Seres, Liza Dalma Sumegi, Alexander Gal, Akos Ilias, Papp Janos, Krisztina Barbara Gecse, Talat Bessisow, Waqqas Afif, Alain Bitton, Zsuzsanna Vegh, Peter
Digestive and Liver Disease.2018; 50(1): 37. CrossRef
Quality indicators in inflammatory bowel disease
Sameer K. Berry, Gil Y. Melmed
Intestinal Research.2018; 16(1): 43. CrossRef
Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 1: Risk assessment
Dong II Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin‐Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
Journal of Gastroenterology and Hepatology.2018; 33(1): 20. CrossRef
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
Intestinal Research.2018; 16(1): 4. CrossRef
Incidence and Risk Factor Analysis of Thromboembolic Events in East Asian Patients With Inflammatory Bowel Disease, a Multinational Collaborative Study
Meng-Tzu Weng, Sang Hyoung Park, Katsuyoshi Matsuoka, Chien-Chih Tung, Jae Yong Lee, Chin-Hao Chang, Suk-Kyun Yang, Mamoru Watanabe, Jau-Min Wong, Shu-Chen Wei
Inflammatory Bowel Diseases.2018; 24(8): 1791. CrossRef
Assessment of factors associated with smoking cessation at diagnosis or during follow‐up of Crohn's disease
Eun Mi Song, Gwang‐Un Kim, Myeongsook Seo, Sung Wook Hwang, Sang Hyoung Park, Eunja Kwon, Ho‐Su Lee, Dong‐Hoon Yang, Kyung‐Jo Kim, Byong Duk Ye, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang
Journal of Gastroenterology and Hepatology.2018; 33(1): 180. CrossRef
Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?
Matthew Strohl, Lorant Gonczi, Zsuzsanna Kurt, Talat Bessissow, Peter L Lakatos
World Journal of Gastroenterology.2018; 24(22): 2363. CrossRef
Changing treatment paradigms for the management of inflammatory bowel disease
Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
The Korean Journal of Internal Medicine.2018; 33(1): 28. CrossRef
IBD2020 global forum: results of an international patient survey on quality of care
Peter Irving, Johan Burisch, Richard Driscoll, Mats Olsson, John R Fullarton, Barry S Rodgers-Gray, Simon PL Travis
Intestinal Research.2018; 16(4): 537. CrossRef

6,941 View
79 Download
23 Web of Science
22 Crossref

Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2^nd Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul: Hiroshi Nakase, Bora Keum, Byoung Duk Ye, Soo Jung Park, Hoon Sup Koo, Chang Soo Eun; Intest Res 2016;14(3):231-239. Published online June 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.3.231

Abstract PDF PubReader ePub

Background/Aims

Inflammatory bowel disease (IBD) management guidelines have been released from Western countries, but no adequate data on the application of these guidelines in Asian countries and no surveys on the treatment of IBD in real practice exist. Since there is a growing need for a customized consensus for IBD treatment in Asian countries, Asian Organization of Crohn's and Colitis performed a multinational survey of medical doctors who treat IBD patients in Asian countries.

Methods

A questionnaire was developed between August 2013 and November 2013. It was composed of 4 domains: personal information, IBD diagnosis, IBD treatment, and quality of IBD care. Upon completion of the questionnaire, a web-based survey was conducted between 17 March 2014 and 12 May 2014.

Results

In total, 353 medical doctors treating IBD from ten Asian countries responded to the survey. This survey data suggested a difference in available medical treatments (budesonide, tacrolimus) among Asian countries. Therapeutic strategies regarding refractory IBD (acute severe ulcerative colitis [UC] refractory to intravenous steroids and refractory Crohn's disease [CD]) and active UC were coincident, however, induction therapies for mild to moderate inflammatory small bowel CD are different among Asian countries.

Conclusions

This survey demonstrated that current therapeutic approaches and clinical management of IBD vary among Asian countries. Based on these results and discussions, we hope that optimal management guidelines for Asian IBD patients will be developed.

Citations

Citations to this article as recorded by

Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im
Intestinal Research.2023; 21(3): 353. CrossRef
Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
Journal of Gastroenterology and Hepatology.2023; 38(4): 523. CrossRef
Management and monitoring of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group: Surgical management,
Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen Calixto Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
Journal of Gastroenterology and Hepatology.2023; 38(4): 510. CrossRef
Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
Intestinal Research.2023; 21(3): 339. CrossRef
How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?
Jihye Park
Intestinal Research.2023; 21(3): 275. CrossRef
Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia
Chenwen Cai, Juntao Lu, Lijie Lai, Dongjuan Song, Jun Shen, Jinlu Tong, Qing Zheng, Kaichun Wu, Jiaming Qian, Zhihua Ran
Intestinal Research.2022; 20(2): 213. CrossRef
Indications, Postoperative Management, and Long-term Prognosis of Crohn’s Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West
Jeanine H C Arkenbosch, Joyce W Y Mak, Jacky C L Ho, Evelien M J Beelen, Nicole S Erler, Frank Hoentjen, Alexander G L Bodelier, Gerard Dijkstra, Mariëlle Romberg-Camps, Nanne K H de Boer, Laurents P S Stassen, Andrea E van der Meulen, Rachel West, Oddeke
Inflammatory Bowel Diseases.2022; 28(Supplement): S16. CrossRef
UK Patients of Bangladeshi Descent with Crohn’s Disease Respond Less Well to TNF Antagonists Than Caucasian Patients
Radha Gadhok, Hannah Gordon, Gregory Sebepos-Rogers, Samantha Baillie, Saniath Akbar, Jane E. Abbott, Emma Michael, Omer F. Ahmad, Ben Cooper, James O. Lindsay
Digestive Diseases and Sciences.2020; 65(6): 1790. CrossRef
Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
Hiroshi Nakase
Gut and Liver.2020; 14(1): 7. CrossRef
Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study
Jesus K. Yamamoto-Furusho, Othman Al Harbi, Alessandro Armuzzi, Webber Chan, Enrique Ponce de Leon, Jiaming Qian, Marina Shapina, Murat Toruner, Chia-Hung Tu, Byong Duk Ye, Morgane Guennec, Cecilia Sison, Dirk Demuth, Olga Fadeeva, Qasim M. Rana Khan
Digestive and Liver Disease.2020; 52(8): 869. CrossRef
CYP3A5 Genotype as a Potential Pharmacodynamic Biomarker for Tacrolimus Therapy in Ulcerative Colitis in Japanese Patients
Yuki Yamamoto, Hiroshi Nakase, Minoru Matsuura, Shihoko Maruyama, Satohiro Masuda
International Journal of Molecular Sciences.2020; 21(12): 4347. CrossRef
Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia
Siew C Ng, Joyce Wing Yan Mak, Partha Pal, Rupa Banerjee
The Lancet Gastroenterology & Hepatology.2020; 5(12): 1089. CrossRef
Improving the quality of care for inflammatory bowel disease
Byong Duk Ye, Simon Travis
Intestinal Research.2019; 17(1): 45. CrossRef
Increased risk of atrial fibrillation in patients with inflammatory bowel disease: A nationwide population-based study
You-Jung Choi, Eue-Keun Choi, Kyung-Do Han, Jiesuck Park, Inki Moon, Euijae Lee, Won-Seok Choe, So-Ryoung Lee, Myung-Jin Cha, Woo-Hyun Lim, Seil Oh
World Journal of Gastroenterology.2019; 25(22): 2788. CrossRef
Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries
Taku Kobayashi, Tadakazu Hisamatsu, Yasuo Suzuki, Haruhiko Ogata, Akira Andoh, Toshimitsu Araki, Ryota Hokari, Hideki Iijima, Hiroki Ikeuchi, Yoh Ishiguro, Shingo Kato, Reiko Kunisaki, Takayuki Matsumoto, Satoshi Motoya, Masakazu Nagahori, Shiro Nakamura,
Intestinal Research.2018; 16(2): 168. CrossRef
Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
Intestinal Research.2018; 16(3): 400. CrossRef
Computed Tomography and Magnetic Resonance Small Bowel Enterography
Seong Ho Park, Byong Duk Ye, Tae Young Lee, Joel G. Fletcher
Gastroenterology Clinics of North America.2018; 47(3): 475. CrossRef
Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome
Takahiko Toyonaga, Taku Kobayashi, Masaru Nakano, Eiko Saito, Satoko Umeda, Shinji Okabayashi, Ryo Ozaki, Toshifumi Hibi, Emiko Mizoguchi
PLOS ONE.2017; 12(9): e0185131. CrossRef
Peptide Receptor-Targeted Fluorescent Probe: Visualization and Discrimination between Chronic and Acute Ulcerative Colitis
Meiying Zeng, Andong Shao, Hui Li, Yan Tang, Qiang Li, Zhiqian Guo, Chungen Wu, Yingsheng Cheng, He Tian, Wei-Hong Zhu
ACS Applied Materials & Interfaces.2017; 9(15): 13029. CrossRef
Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study
Wei-Chen Lin, Jen-Wei Chou, Hsu-Heng Yen, Wen-Hung Hsu, Hung-Hsin Lin, Jen-Kou Lin, Chiao-Hsiung Chuang, Tien-Yu Huang, Horng-Yuan Wang, Shu-Chen Wei, Jau-Min Wong
Intestinal Research.2017; 15(4): 487. CrossRef
CT Enterography for Surveillance of Anastomotic Recurrence within 12 Months of Bowel Resection in Patients with Crohn's Disease: An Observational Study Using an 8-Year Registry
In Young Choi, Sang Hyoung Park, Seong Ho Park, Chang Sik Yu, Yong Sik Yoon, Jong Lyul Lee, Byong Duk Ye, Ah Young Kim, Suk-Kyun Yang
Korean Journal of Radiology.2017; 18(6): 906. CrossRef
Is Adsorptive Granulocyte and Monocyte Apheresis Effective as an Alternative Treatment Option in Patients with Ulcerative Colitis?
Seong Ran Jeon
Gut and Liver.2017; 11(2): 171. CrossRef
Cancer Risk in the Early Stages of Inflammatory Bowel Disease in Korean Patients: A Nationwide Population-based Study
Yoon Suk Jung, Minkyung Han, Sohee Park, Won Ho Kim, Jae Hee Cheon
Journal of Crohn's and Colitis.2017; 11(8): 954. CrossRef
Results of the first survey for the current status of inflammatory bowel disease management in Asian countries
Ji Won Kim
Intestinal Research.2016; 14(3): 199. CrossRef

7,273 View
106 Download
25 Web of Science
24 Crossref

Diagnosis of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2^nd Asian Organization for Crohn's and Colitis (AOCC) meeting in Seoul: Eun Soo Kim, Minhu Chen, Jun Lee, Chang-Kyun Lee, You Sun Kim; Intest Res 2016;14(3):224-230. Published online June 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.3.224

Abstract PDF PubReader ePub

Background/Aims

As the number of Asian patients with inflammatory bowel disease (IBD) has increased recently, there is a growing need to improve IBD care in this region. This study is aimed at determining how Asian countries are currently dealing with their IBD patients in terms of diagnosis.

Methods

A questionnaire was designed by the organizing committee of Asian Organization for Crohn's and Colitis, for a multinational web-based survey conducted between March 2014 and May 2014.

Results

A total of 353 Asian medical doctors treating IBD patients responded to the survey (114 in China, 88 in Japan, 116 in Korea, and 35 in other Asian countries). Most of the respondents were gastroenterologists working in an academic teaching hospital. While most of the doctors from China, Japan, and Korea use their own national guidelines for IBD diagnosis, those from other Asian countries most commonly adopt the European Crohn's Colitis Organisation's guideline. Japanese doctors seldom adopt the Montreal classification for IBD. The most commonly used activity scoring system for ulcerative colitis is the Mayo score in all countries except China, whereas that for Crohn's disease (CD) is the Crohn's Disease Activity Index. The most available tool for small-bowel evaluation in CD patients differs across countries. Many physicians administer empirical anti-tuberculous medications before the diagnosis of CD.

Conclusions

The results of this survey demonstrate that Asian medical doctors have different diagnostic approaches for IBD. This knowledge would be important in establishing guidelines for improving the care of IBD patients in this region.

Citations

Citations to this article as recorded by

Vaccination in patients with inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Su Bum Park, Kyeong Ok Kim, Hong Sub Lee, Chang Hwan Choi, Shu Chen Wei, Min Hu Chen, Katsuyoshi Matsuoka
Intestinal Research.2023; 21(3): 363. CrossRef
Diagnosis of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Han Hee Lee, Jae Jun Park, Bo-In Lee, Ida Hilmi, Jose Sollano, Zhi Hua Ran
Intestinal Research.2023; 21(3): 328. CrossRef
Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
Intestinal Research.2023; 21(3): 339. CrossRef
Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im
Intestinal Research.2023; 21(3): 353. CrossRef
Changing treatment paradigms for the management of inflammatory bowel disease
Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
The Korean Journal of Internal Medicine.2018; 33(1): 28. CrossRef
Citrus aurantium L. and Its Flavonoids Regulate TNBS-Induced Inflammatory Bowel Disease through Anti-Inflammation and Suppressing Isolated Jejunum Contraction
Wei He, Yongmin Li, Mengyang Liu, Haiyang Yu, Qian Chen, Yue Chen, Jingya Ruan, Zhijuan Ding, Yi Zhang, Tao Wang
International Journal of Molecular Sciences.2018; 19(10): 3057. CrossRef
FKBP11 protects intestinal epithelial cells against inflammation‑induced apoptosis via the JNK‑caspase pathway in Crohn's disease
Xiaotong Wang, Xiaopeng Cui, Chuanwu Zhu, Ming Li, Juan Zhao, Zhongyi Shen, Xiaohang Shan, Liang Wang, Han Wu, Yanting Shen, You Ni, Dongmei Zhang, Guoxiong Zhou
Molecular Medicine Reports.2018;[Epub] CrossRef
Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease
Hyun Jung Lee, Jae Hee Cheon
Intestinal Research.2017; 15(3): 311. CrossRef
Advances in Methods for Diagnosis of Chronic Mycobacterial Infections of Gastrointestinal Tract
Vishwa M Katoch
Journal of Gastrointestinal Infections.2017; 7(1): 26. CrossRef
Advances in Methods for Diagnosis of Chronic Mycobacterial Infections of Gastrointestinal Tract
Vishwa M Katoch
Journal of Gastrointestinal Infections.2017; 7(1): 26. CrossRef
Endoscopic Diagnosis and Differentiation of Inflammatory Bowel Disease
Ji Min Lee, Kang-Moon Lee
Clinical Endoscopy.2016; 49(4): 370. CrossRef
Results of the first survey for the current status of inflammatory bowel disease management in Asian countries
Ji Won Kim
Intestinal Research.2016; 14(3): 199. CrossRef

5,467 View
57 Download
11 Web of Science
12 Crossref

Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries: Shu Chen Wei; Intest Res 2016;14(3):218-223. Published online June 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.3.218

Abstract PDF PubReader ePub

Background/Aims

The cost of caring for patients with inflammatory bowel disease (IBD) is high. Without government support, the cost burden will unavoidably rest on the patients and their family. However, the government providing full support will place a large financial burden on the health-care systems of a country. The aim of this study is to understand the current status of public medical insurance systems in caring for IBD patients among Asian countries.

Methods

Questionnaires inquiring about the availability of public health systems; medical, diagnostic, and endoscopy costs; and coverage rate of biologics use were designed and sent to IBD experts in each of the Asian countries studied. The results were summarized according to the feedback from the responders.

Results

The public health insurance coverage rate is high in Taiwan, Japan, South Korea, China, Hong Kong, and Singapore; but low in Malaysia and India. This probably affected the use of expensive medications mostly, such as biologics, as we found that the percentage of Crohn's disease (CD) treated with biologics were as high as 30%–40% in Japan, where the government covers all expenses for IBD patients. In India, the percentage maybe as low as 1% for CD patients, most of whom need to pay for the biologics themselves.

Conclusions

There were differences in the public health insurance systems among the Asian countries studied. This reportprovidesthe background information to understand the differences in the treatment of IBD patients among Asian countries.

Citations

Citations to this article as recorded by

Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition
Filiz Akyüz, Yoon Kyo An, Jakob Begun, Satimai Aniwan, Huu Hoang Bui, Webber Chan, Chang Hwan Choi, Nazeer Chopdat, Susan J Connor, Devendra Desai, Emma Flanagan, Taku Kobayashi, Allen Yu-Hung Lai, Rupert W Leong, Alex Hwong-Ruey Leow, Wai Keung Leung, Ju
Intestinal Research.2025; 23(1): 37. CrossRef
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis
Johannes Hasskamp, Christian Meinhardt, Petrease H Patton, Antje Timmer
Cochrane Database of Systematic Reviews.2025;[Epub] CrossRef
Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn’s disease
Tsubasa Oike, Naoki Akizue, Yuki Ohta, Hirotaka Koseki, Masaya Saito, Yuya Yokoyama, Yushi Imai, Takashi Taida, Kenichiro Okimoto, Keiko Saito, Sadahisa Ogasawara, Tomoaki Matsumura, Tomoo Nakagawa, Makoto Arai, Tatsuro Katsuno, Yoshihiro Fukuda, Yoshio K
Arab Journal of Gastroenterology.2024; 25(3): 257. CrossRef
Reflections from Chinese and Japanese Physicians on Medical Disputes
Hua Xu, Yining Ruan, Taketoshi Okita, Masao Tabata, Yasuhiro Kadooka, Atsushi Asai
Asian Bioethics Review.2024; 16(4): 683. CrossRef
Study of Inflammatory Bowel Disease in Patients Undergoing Colonoscopy at a Tertiary Center of Nepal
Kumud Bhattarai, Ajit Khanal, Ramila Shrestha, Mukesh S Paudel
Cureus.2024;[Epub] CrossRef
The treatment of inflammatory bowel disease with monoclonal antibodies in Asia
Yu Chen, Guolin Zhang, Yuewen Yang, Shuangshuang Zhang, Haozheng Jiang, Kang Tian, Arenbaoligao, Dapeng Chen
Biomedicine & Pharmacotherapy.2023; 157: 114081. CrossRef
Identification of the informational and supportive needs of patients diagnosed with inflammatory bowel disease: a scoping review
Narges Norouzkhani, Mahbobeh Faramarzi, Sara Ghodousi Moghadam, Mohammad Amin Karimi, Javad Shokri Shirvani, Ali Bahari, Mahdie ShojaeiBaghini, Saeid Eslami, Hamed Tabesh
Frontiers in Psychology.2023;[Epub] CrossRef
IBD barriers across the continents – East Asia
Joyce Wing Yan Mak, Agnes Hiu Yan Ho, Siew Chien Ng
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef
Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, South‐East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Disease‐Emerging Nations' Consortium
Rupa Banerjee, Partha Pal, Ida Hilmi, Uday C Ghoshal, Devendra C Desai, Mohammed Masudur Rahman, Usha Dutta, Syed A Mohiuddin, Munnera Al Mohannadi, Mathew Philip, Ganesh N Ramesh, Madunil A Niriella, Arjuna P De Silva, Hithanadura Janaka de Silva, Pises
Journal of Gastroenterology and Hepatology.2022; 37(6): 1004. CrossRef
Managing pediatric psoriasis: update on treatments and challenges—a review
A. A. Hebert, J. Browning, P. C. Kwong, A. M. Duarte, H. N. Price, E. Siegfried
Journal of Dermatological Treatment.2022; 33(5): 2433. CrossRef
Landscape of inflammatory bowel disease in Singapore
Daren Low, Nidhi Swarup, Toshiyuki Okada, Emiko Mizoguchi
Intestinal Research.2022; 20(3): 291. CrossRef
Inflammatory bowel disease in India: challenges and opportunities
Alice Snell, Jonathan Segal, Jimmy Limdi, Rupa Banerjee
Frontline Gastroenterology.2021; 12(5): 390. CrossRef
Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia
Shu-Chen Wei, Jose Sollano, Yee Tak Hui, Wei Yu, Paul V. Santos Estrella, Lyndon John Q. Llamado, Nana Koram
Expert Review of Gastroenterology & Hepatology.2021; 15(3): 275. CrossRef
Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis—Patients’ and Physicians’ View
Marla C Dubinsky, Kenji Watanabe, Pauliina Molander, Laurent Peyrin-Biroulet, Michele Rubin, Gil Y Melmed, J Jasper Deuring, John Woolcott, Joseph C Cappelleri, Kathy Steinberg, Susan Connor
Inflammatory Bowel Diseases.2021; 27(11): 1747. CrossRef
Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
Ting Zhou, Yanan Sheng, Haijing Guan
Advances in Therapy.2021; 38(8): 4233. CrossRef
Impact of Demographic, Clinical and Psychosocial Variables on Drug Adherence and Outcomes in Indian Patients With Inflammatory Bowel Disease
Rupa Banerjee, Partha Pal, Bhargavi Adigopula, Duvvuru Nageshwar Reddy
Journal of Clinical Gastroenterology.2021; 55(10): e92. CrossRef
Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance
Tina Aswani-Omprakash, Vishal Sharma, Shrinivas Bishu, Madhura Balasubramaniam, Sumit Bhatia, Neilanjan Nandi, Neha D Shah, Parakkal Deepak, Shaji Sebastian
The Lancet Gastroenterology & Hepatology.2021; 6(11): 884. CrossRef
Incidence and Outcomes of Perianal Disease in an Asian Population with Crohn’s Disease: A Nationwide Population-Based Study
Eun Mi Song, Ho-Su Lee, Ye-Jee Kim, Eun Hye Oh, Nam Seok Ham, Jeongseok Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Jong Lyul Lee, Yong Sik Yoon, Chang Sik Yu, Suk-Kyun Yang
Digestive Diseases and Sciences.2020; 65(4): 1189. CrossRef
Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
Digestive Diseases and Sciences.2020; 65(5): 1436. CrossRef
Review of the epidemiology and burden of ulcerative colitis in Latin America
Paulo Gustavo Kotze, Flavio Steinwurz, Carlos Francisconi, Cyrla Zaltman, Marcia Pinheiro, Leonardo Salese, Dario Ponce de Leon
Therapeutic Advances in Gastroenterology.2020;[Epub] CrossRef
Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia
Siew C Ng, Joyce Wing Yan Mak, Partha Pal, Rupa Banerjee
The Lancet Gastroenterology & Hepatology.2020; 5(12): 1089. CrossRef
Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study
Hsu-Heng Yen, Meng-Tzu Weng, Chien-Chih Tung, Yu-Ting Wang, Yuan Ting Chang, Chin-Hao Chang, Ming-Jium Shieh, Jau-Min Wong, Shu-Chen Wei
Intestinal Research.2019; 17(1): 54. CrossRef
Incidence and clinical impact of perianal disease in patients with ulcerative colitis: A nationwide population‐based study
Eun Mi Song, Ho‐Su Lee, Ye‐Jee Kim, Eun Hye Oh, Nam Seok Ham, Jeongseok Kim, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Byong Duk Ye, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang
Journal of Gastroenterology and Hepatology.2019; 34(6): 1011. CrossRef
Initial medical and surgical management of inflammatory bowel disease in the biologic era: A comparison between the United States and China
Sanskriti Varma, Jun Hu, Ambar Mehta, Yiran Song, Angela Park, Min Zhi, Susan Hutfless
JGH Open.2019; 3(3): 234. CrossRef
Regaining normality: A grounded theory study of the illness experiences of Chinese patients living with Crohn’s disease
Jiayin Ruan, Yunxian Zhou
International Journal of Nursing Studies.2019; 93: 87. CrossRef
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chia
Journal of Gastroenterology and Hepatology.2019; 34(8): 1296. CrossRef
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chia
Intestinal Research.2019; 17(3): 285. CrossRef
Stopping anti‐tumour necrosis factor therapy in patients with perianal Crohn’s disease
Joyce Wing Yan Mak, Whitney Tang, Terry Cheuk Fung Yip, Zhi Hua Ran, Shu Chen Wei, Vineet Ahuja, Sudheer Kumar, Wai Keung Leung, Ida Hilmi, Julajak Limsrivilai, Satimai Aniwan, Belsy C. Y. Lam, Kam Hon Chan, Ka Man Ng, Chi Man Leung, Michael K. K. Li, Fu
Alimentary Pharmacology & Therapeutics.2019; 50(11-12): 1195. CrossRef
Increased Risk of Herpes Zoster Infection in Patients With Inflammatory Bowel Diseases in Korea
Kiju Chang, Ho-Su Lee, Ye-Jee Kim, Seon-Ok Kim, Sung-Han Kim, Sun-Ho Lee, Eun Mi Song, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
Clinical Gastroenterology and Hepatology.2018; 16(12): 1928. CrossRef
An Intergenic Variant rs9268877 Between HLA-DRA and HLA-DRB Contributes to the Clinical Course and Long-term Outcome of Ulcerative Colitis
Ho-Su Lee, Suk-Kyun Yang, Myunghee Hong, Seulgi Jung, Byoung Mok Kim, Jung Won Moon, Sang Hyoung Park, Byong Duk Ye, Seak Hee Oh, Kyung Mo Kim, Yong Sik Yoon, Chang Sik Yu, Jiwon Baek, Cue Hyunkyu Lee, Buhm Han, Jianjun Liu, Talin Haritunians, Dermot P B
Journal of Crohn's and Colitis.2018;[Epub] CrossRef
Paradigm Shift of Healthcare Cost for Patients with Inflammatory Bowel Diseases: A Claims Data-Based Analysis in Japan
Shota Saito, Kyoko Nakazawa, Kenji Suzuki, Takashi Ishikawa, Kouhei Akazawa
Gastrointestinal Disorders.2018; 1(1): 120. CrossRef
Overall and cause‐specific mortality in Korean patients with inflammatory bowel disease: A hospital‐based cohort study
Ho‐Su Lee, Jaewon Choe, Seon‐Ok Kim, Sun‐Ho Lee, Hyo Jeong Lee, Hyungil Seo, Gwang‐Un Kim, Myeongsook Seo, Eun Mi Song, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Kyung‐Jo Kim, Byong Duk Ye, Jeong‐Sik Byeon, Seung‐Jae Myung, Yong Sik Yoon, Chang S
Journal of Gastroenterology and Hepatology.2017; 32(4): 782. CrossRef
Emerging biologics in inflammatory bowel disease
Heyson Chi-hey Chan, Siew Chien Ng
Journal of Gastroenterology.2017; 52(2): 141. CrossRef
Balloon-Assisted Enteroscopy and Capsule Endoscopy in Suspected Small Bowel Crohn’s Disease
Hsu-Heng Yen, Chen-Wang Chang, Jen-Wei Chou, Shu-Chen Wei
Clinical Endoscopy.2017; 50(5): 417. CrossRef
Pivot to Asia: inflammatory bowel disease burden
Prashant Singh, Ashwin Ananthakrishnan, Vineet Ahuja
Intestinal Research.2017; 15(1): 138. CrossRef
Short-Term Clinical Response to Corticosteroids Can Predict Long-Term Natural History of Ulcerative Colitis: Prospective Study Experience
Tarun Rai, Bikash Narayan Choudhury, Saurabh Kedia, Sawan Bopanna, Pratap Mouli Venigalla, Sushil Kumar Garg, Vikas Singla, Govind Makharia, Vineet Ahuja
Digestive Diseases and Sciences.2017; 62(4): 1025. CrossRef
Results of the first survey for the current status of inflammatory bowel disease management in Asian countries
Ji Won Kim
Intestinal Research.2016; 14(3): 199. CrossRef

18,511 View
79 Download
36 Web of Science
37 Crossref

Comparison of the efficacy of disinfectants in automated endoscope reprocessors for colonoscopes: tertiary amine compound (Sencron2®) versus ortho-phthalaldehyde (Cidex®OPA): Hyun Il Seo, Dae Sung Lee, Eun Mi Yoon, Min-Jung Kwon, Hyosoon Park, Yoon Suk Jung, Jung Ho Park, Chong Il Sohn, Dong Il Park; Intest Res 2016;14(2):178-182. Published online April 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.2.178

Abstract PDF PubReader ePub

Background/Aims

To prevent the transmission of pathogens by endoscopes, following established reprocessing guidelines is critical. An ideal reprocessing step is simple, fast, and inexpensive. Here, we evaluated and compared the efficacy and safety of two disinfectants, a tertiary amine compound (TAC) and ortho-phthalaldehyde (OPA).

Methods

A total of 100 colonoscopes were randomly reprocessed using two same automated endoscope reprocessors, according to disinfectant. The exposure time was 10 minutes for 0.55% OPA (Cidex® OPA, Johnson & Johnson) and 5 minutes for 4% TAC (Sencron2®, Bab Gencel Pharma & Chemical Ind. Co.). Three culture samples were obtained from each colonoscope after reprocessing.

Results

A total of nine samples were positive among the 300 culture samples. The positive culture rate was not statistically different between the two groups (4% for OPA and 2% for TAC, P=0.501). There were no incidents related to safety during the study period.

Conclusions

TAC was non-inferior in terms of reprocessing efficacy to OPA and was safe to use. Therefore, TAC seems to be a good alternative disinfectant with a relatively short exposure time and is also less expensive than OPA.

Citations

Citations to this article as recorded by

What doesn’t kill biofilm, makes them stronger: critical methodological considerations for endoscope reprocessing
R. Kanaujia, A. Sharma, M. Biswal, V. Singh
Journal of Hospital Infection.2025; 156: 135. CrossRef
Synthesis, Characterization and Investigation of Antimicrobial Activity of Orthophtaldehyde Nanoflowers
Gülten CAN SEZGİN, Nilay ILDİZ
Middle Black Sea Journal of Health Science.2023; 9(2): 245. CrossRef
A Manufacturer and User Facility Device Experience Analysis of Upper Aerodigestive Endoscopy Contamination: Is Flexible Laryngoscopy Different?
Roy Jiang, David A. Kasle, Faisal Alzahrani, Nikita Kohli, Michael Z. Lerner
The Laryngoscope.2021; 131(3): 598. CrossRef
Electrochemical and Spectrometric Study of Reactivity of Orthophthalaldehyde with Hydroxylamine: Mechanistic Considerations
Joël Donkeng‐Dazie, Jiří Urban, Jiří Ludvík
ChemistrySelect.2021; 6(20): 4881. CrossRef
Reactivity of orthophthalaldehyde with aliphatic, alicyclic and aromatic primary diamines: Electrochemical study and mechanistic considerations
Joël Donkeng Dazie, Alan Liška, Jiří Urban, Jiří Ludvík
Journal of Electroanalytical Chemistry.2018; 821: 131. CrossRef
Efficacy of Peracetic Acid (EndoPA®) for Disinfection of Endoscopes
Ji Min Lee, Kang-Moon Lee, Dae Bum Kim, Se Eun Go, Sungwoo Ko, Yoongoo Kang, Solim Hong
The Korean Journal of Gastroenterology.2018; 71(6): 319. CrossRef
Planarity of substituted pyrrole and furan rings in (3R*, 1′S*, 3′R*)-3-(1′-tert-butylamino-1′H, 3′ H-benzo[c]furan-3′-yl)-2-tert-butyl-2,3-dihydro-1H-benzo[c]pyrrol-1-one
Joel Donkeng Dazie, Alan Liška, Jiří Ludvík, Jan Fábry, Michal Dušek, Václav Eigner
Zeitschrift für Kristallographie - Crystalline Materials.2017; 232(6): 441. CrossRef

7,417 View
53 Download
4 Web of Science
7 Crossref

Do we need colonoscopy verification in patients with fundic gland polyp?: Hee Sook Lee, Younjeong Choi, Ja Young Jung, Young-Jun Sung, Dong Won Ahn, Ji Bong Jeong, Byeong Gwan Kim, Kook Lae Lee, Seong-Joon Koh, Ji Won Kim; Intest Res 2016;14(2):172-177. Published online April 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.2.172

Abstract PDF PubReader ePub

Background/Aims

The aim of this study was to evaluate the prevalence of colorectal neoplasia in subjects with fundic gland polyps (FGPs) and the relationship between FGPs and colorectal neoplasia in Korea.

Methods

We analyzed 128 consecutive patients with FPGs who underwent colonoscopy between January 2009 and December 2013. For each case, age- (±5 years) and sex-matched controls were identified from among patients with hyperplastic polyps, gastric neoplasms, and healthy controls. Clinical characteristics were reviewed from medical records, colonoscopic findings, pathologic findings, and computed tomography images. The outcome was evaluated by comparison of advanced colonic neoplasia detection rates.

Results

Of the 128 patients, seven (5.1%) had colon cancers and seven (5.1%) had advanced adenomas. A case-control study revealed that the odds of detecting a colorectal cancer was 3.8 times greater in patients with FGPs than in the age- and sex-matched healthy controls (odds ratio [OR], 3.80; 95% confidence interval [CI], 1.09–13.24; P =0.04) and 4.1 times greater in patients with FGPs than in healthy controls over 50 years of age (OR, 4.10; 95% CI, 1.16–14.45; P =0.04). Among patients with FGPs over 50 years old, male sex (OR, 4.83; 95% CI, 1.23–18.94; P =0.02), and age (OR, 9.90; 95% CI, 1.21–81.08; P =0.03) were associated with an increased prevalence of advanced colorectal neoplasms.

Conclusions

The yield of colonoscopy in colorectal cancer patients with FGPs was substantially higher than that in average-risk subjects. Colonoscopy verification is warranted in patients with FGPs, especially in those 50 years of age or older.

Citations

Citations to this article as recorded by

Current Guidelines and Advances in the Management of Fundic Gland Polyps
Majed Ali, Lynn Srour, Mustapha Bitar, Karam Karam, Ihab I. El Hajj, Elias Fiani
Journal of Gastroenterology and Hepatology.2025; 40(6): 1374. CrossRef
Cold snare polypectomy for fundic gland polyps
Chi‐Hung Chen, Jen‐Chieh Huang, Jeng‐Shiann Shin
Advances in Digestive Medicine.2022; 9(1): 17. CrossRef
Clinical features of fundic gland polyps and their correlation with colorectal tumors
Xue-Mei Yang, Hong Xu
World Chinese Journal of Digestology.2020; 28(20): 1036. CrossRef
Parietalzellhypertrophie und Drüsenkörperzysten
M. Venerito, A. Canbay, M. Vieth
Der Gastroenterologe.2018; 13(2): 90. CrossRef

7,111 View
43 Download
5 Web of Science
4 Crossref

Usefulness of endoscopic resection using the band ligation method for rectal neuroendocrine tumors: Ju Seung Kim, Yoon Jae Kim, Jun-Won Chung, Jung Ho Kim, Kyoung Oh Kim, Kwang An Kwon, Dong Kyun Park, Jung Suk An; Intest Res 2016;14(2):164-171. Published online April 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.2.164

Abstract PDF PubReader ePub

Background/Aims

Rectal neuroendocrine tumors (NETs) are among the most common of gastrointestinal NETs. Due to recent advances in endoscopy, various methods of complete endoscopic resection have been introduced for small (≤10 mm) rectal NETs. However, there is a debate about the optimal treatment for rectal NETs. In our study, we aimed to evaluate the efficacy and feasibility of endoscopic resection using pneumoband and elastic band (ER-BL) for rectal NETs smaller than 10 mm in diameter.

Methods

A total of 55 patients who were diagnosed with rectal NET from January 2004 to December 2011 at Gil Medical Center were analyzed retrospectively. Sixteen patients underwent ER-BL. For comparison, 39 patients underwent conventional endoscopic mucosal resection (EMR).

Results

There was a markedly lower deep margin positive rate for ER-BL than for conventional EMR (6% [1/16] vs. 46% [18/39], P=0.029). Four patients who underwent conventional EMR experienced perforation or bleeding. However, they recovered within a few days. On the other hand, patients whounderwent endoscopic resection using a pneumoband did not experience any complications. In multivariate analysis, ER-BL (P=0.021) was independently associated with complete resection.

Conclusions

ER-BL is an effective endoscopic treatment with regards to deep margin resection for rectal NET smaller than 10 mm.

Citations

Citations to this article as recorded by

Risk factors for residual tumors in histologically incompletely resected rectal neuroendocrine tumors
Jung-Bin Park, Ga Hee Kim, Minjun Kim, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Seok-Byung Lim, Seung-Mo Hong, Dong-Hoon Yang
Digestive and Liver Disease.2025; 57(7): 1473. CrossRef
Current status of endoscopic resection for small rectal neuroendocrine tumors
Jian-Ning Liu, Hui Chen, Nian Fang
World Journal of Gastroenterology.2025;[Epub] CrossRef
Endoscopic treatments for rectal neuroendocrine tumors: a systematic review and network meta-analysis
Jie Chen, Jianfang Ye, Xiong Zheng, Jianyong Chen
Journal of Gastrointestinal Surgery.2024; 28(3): 301. CrossRef
Endoscopic mucosal resection using anchored snare Tip-in versus precut technique for small rectal neuroendocrine tumors
Seung Wook Hong, Dong-Hoon Yang, Yoo Jin Lee, Dong Hoon Baek, Jaeyoung Chun, Hyun Gun Kim, Sung Joo Kim, Seung-Mo Hong, Dae-Seong Myung
The Korean Journal of Internal Medicine.2024; 39(2): 238. CrossRef
Outcome of Endoscopic Resection of Rectal Neuroendocrine Tumors ≤ 10 mm
Roberta Elisa Rossi, Maria Terrin, Silvia Carrara, Roberta Maselli, Alexia Francesca Bertuzzi, Silvia Uccella, Andrea Gerardo Antonio Lania, Alessandro Zerbi, Cesare Hassan, Alessandro Repici
Diagnostics.2024; 14(14): 1484. CrossRef
Clinical outcomes of endoscopic resection for rectal neuroendocrine tumors: Advantages of endoscopic submucosal resection with a ligation device compared to conventional EMR and ESD
Yuki Kamigaichi, Ken Yamashita, Shiro Oka, Hirosato Tamari, Yasutsugu Shimohara, Tomoyuki Nishimura, Katsuaki Inagaki, Yuki Okamoto, Hidenori Tanaka, Ryo Yuge, Yuji Urabe, Koji Arihiro, Shinji Tanaka
DEN Open.2022;[Epub] CrossRef
Endoscopic Mucosal Resection in Children
David S. Vitale, Kelly Wang, Laith H. Jamil, Kenneth H. Park, Quin Y. Liu
Journal of Pediatric Gastroenterology and Nutrition.2022; 74(1): 20. CrossRef
Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance
Camilla Gallo, Roberta Elisa Rossi, Federica Cavalcoli, Federico Barbaro, Ivo Boškoski, Pietro Invernizzi, Sara Massironi
World Journal of Gastroenterology.2022; 28(11): 1123. CrossRef
Comparison of underwater endoscopic mucosal resection and endoscopic submucosal dissection of rectal neuroendocrine tumors (with videos)
Sung Sil Park, Kyung Su Han, Bun Kim, Byung Chang Kim, Chang Won Hong, Dae Kyung Sohn, Hee Jin Chang
Gastrointestinal Endoscopy.2020; 91(5): 1164. CrossRef
Treatment Results of Endoscopic Mucosal Resection with a Ligation Device for Duodenal Neuroendocrine Tumors
Ai Fujimoto, Motoki Sasaki, Osamu Goto, Tadateru Maehata, Yasutoshi Ochiai, Motohiko Kato, Atsushi Nakayama, Teppei Akimoto, Jyunko Kuramoto, Yuichiro Hayashi, Kaori Kameyama, Naohisa Yahagi
Internal Medicine.2019; 58(6): 773. CrossRef
Endoscopic submucosal resection with an endoscopic variceal ligation device for the treatment of rectal neuroendocrine tumors
Masahide Ebi, Shoko Nakagawa, Yoshiharu Yamaguchi, Yasuhiro Tamura, Shinya Izawa, Yasutaka Hijikata, Takaya Shimura, Yasushi Funaki, Naotaka Ogasawara, Makoto Sasaki, Takashi Joh, Kunio Kasugai
International Journal of Colorectal Disease.2018; 33(12): 1703. CrossRef
Neuroendocrine neoplasms of rectum: A management update
Emilio Bertani, Davide Ravizza, Massimo Milione, Sara Massironi, Chiara Maria Grana, Dario Zerini, Alessandra Nella Piccioli, Giuseppe Spinoglio, Nicola Fazio
Cancer Treatment Reviews.2018; 66: 45. CrossRef

7,032 View
59 Download
14 Web of Science
12 Crossref

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease: Kai-Chun Wu, Zhi Hua Ran, Xiang Gao, Minhu Chen, Jie Zhong, Jian-Qiu Sheng, Michael A Kamm, Simon Travis, Kori Wallace, Nael M Mostafa, Marisa Shapiro, Yao Li, Roopal B Thakkar, Anne M Robinson; Intest Res 2016;14(2):152-163. Published online April 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.2.152

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD).

Methods

Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220–450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received double-blind adalimumab 160/80 mg or 80/40 mg at weeks 0/2, followed by 40 mg at weeks 4 and 6. An open-label extension period occurred from weeks 8–26; patients received 40 mg adalimumab every other week. Serum adalimumab concentration and change from baseline in fecal calprotectin (FC) were measured during the double-blind period. Clinical remission (CDAI <150), response (decrease in CDAI ≥70 points from baseline), and change from baseline in hs-CRP were assessed through week 26. Nonresponder imputation was used for missing categorical data and last observation carried forward for missing hs-CRP/FC values. No formal hypothesis was tested. Adverse events were monitored.

Results

Mean adalimumab serum concentrations during the induction phase were 13.9–18.1 µg/mL (160/80 mg group) and 7.5−9.5 µg/mL (80/40 mg group). During the double-blind period, higher remission/response rates and greater reductions from baseline in hs-CRP and FC were observed with adalimumab 160/80 mg compared to that with 80/40 mg. Adverse event rates were similar among all treatment groups.

Conclusions

Adalimumab serum concentrations in Chinese patients with CD were comparable to those observed previously in Western and Japanese patients. Clinically meaningful remission rates and improvement in inflammatory markers were achieved with both dosing regimens; changes occurred rapidly with adalimumab 160/80 mg induction therapy. No new safety signals were reported.

Citations

Citations to this article as recorded by

Prospective study of an adalimumab combined with partial enteral nutrition in the induction period of Crohn’s disease
Sisi Zhou, Zeyu Huang, Wenjing Hou, Yiting Lin, Jing Yu
Inflammation Research.2024; 73(2): 199. CrossRef
Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis
Brigida Barberio, David J Gracie, Christopher J Black, Alexander C Ford
Gut.2023; 72(2): 264. CrossRef
Seronegative spondyloarthropathy-associated inflammatory bowel disease
Chrong-Reen Wang, Hung-Wen Tsai
World Journal of Gastroenterology.2023; 29(3): 450. CrossRef
Early Change in Fecal Calprotectin Predicts One‐Year Outcome in Children Newly Diagnosed With Ulcerative Colitis
Chenthan Krishnakumar, Ashwin N. Ananthakrishnan, Brendan M. Boyle, Anne M. Griffiths, Neal S. LeLeiko, David R. Mack, James F. Markowitz, Joel R. Rosh, Cary G. Sauer, Thomas D. Walters, Erin Bonkowski, Lee A. Denson, Jeffrey S. Hyams, Subra Kugathasan
Journal of Pediatric Gastroenterology and Nutrition.2022; 74(1): 72. CrossRef
Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis
Gerd R. Burmester, Kenneth B. Gordon, James T. Rosenbaum, Dilek Arikan, Winnie L. Lau, Peigang Li, Freddy Faccin, Remo Panaccione
Advances in Therapy.2020; 37(1): 364. CrossRef
Comparative Evaluation of 4 Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies
Melissa Joyce Sam, Susan Jane Connor, Watson Wa-Sang Ng, Catherine Mei-Ling Toong
Therapeutic Drug Monitoring.2020; 42(6): 821. CrossRef
Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
Intestinal Research.2018; 16(3): 400. CrossRef
Updated treatment strategies for intestinal Behçet’s disease
Yong Eun Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2018; 33(1): 1. CrossRef
Changing treatment paradigms for the management of inflammatory bowel disease
Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
The Korean Journal of Internal Medicine.2018; 33(1): 28. CrossRef
Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn’s Disease: A Hospital-Based Cohort Study from Korea
Hyungil Seo, Byong Duk Ye, Eun Mi Song, Sun-Ho Lee, Kiju Chang, Ho-Su Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
Digestive Diseases and Sciences.2017; 62(10): 2882. CrossRef
Rare occurrence of inflammatory bowel disease in a cohort of Han Chinese ankylosing spondylitis patients- a single institute study
Chrong-Reen Wang, Chia-Tse Weng, Chung-Ta Lee, Kuo-Yuan Huang, Sheng-Min Hsu, Ming-Fei Liu
Scientific Reports.2017;[Epub] CrossRef

7,372 View
107 Download
11 Web of Science
11 Crossref

Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: Jang Wook Lee, Chang Hwan Choi, Ji Hoon Park, Jeong Wook Kim, Sang Bum Kang, Ja Seol Koo, Young-Ho Kim, You Sun Kim, Young Eun Joo, Sae Kyung Chang; Intest Res 2016;14(2):146-151. Published online April 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.2.146

Abstract PDF PubReader ePub

Background/Aims

Anti-tumor necrosis factor (TNF) therapy for active ulcerative colitis (UC) and Crohn's disease (CD) is associated with increased risks of tuberculosis (TB) infection. We analyzed the incidence and clinical features of Korean patients with inflammatory bowel disease (IBD) who developed active TB during anti-TNF therapy.

Methods

Ten cases of active TB developed in patients treated with infliximab (n=592) or adalimumab (n=229) for UC (n=160) or CD (n=661) were reviewed. We analyzed demographics, interval between start of anti-TNF therapy and active TB development, tests for latent TB infection (LTBI), concomitant medications, and the details of diagnosis and treatments for TB.

Results

The incidence of active TB was 1.2% (10/821): 1.5% (9/592) and 0.4% (1/229) in patients receiving infliximab and adalimumab, respectively. The median time to the development of active TB after initiation of anti-TNF therapy was three months (range: 2–36). Three patients had past histories of treatment for TB. Positive findings in a TB skin test (TST) and/or interferon gamma releasing assay (IGRA) were observed in three patients, and two of them received anti-TB prophylaxis. Two patients were negative by both TST and IGRA. The most common site of active TB was the lungs, and the active TB was cured in all patients.

Conclusions

Active TB can develop during anti-TNF therapy in IBD patients without LTBI, and even in those with histories of TB treatment or LTBI prophylaxis. Physicians should be aware of the potential for TB development during anti-TNF therapy, especially in countries with a high prevalence of TB.

Citations

Citations to this article as recorded by

(Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review
Thomas Theo Brehm, Maja Reimann, Niklas Köhler, Christoph Lange
Clinical Microbiology and Infection.2024; 30(8): 989. CrossRef
Real-world effectiveness of ustekinumab in maintenance therapy for Crohn´s disease
O.V. Knyazev, O.B. Schukina, A.V. Kagramanova, A.A. Lishchinskaya, I.A. Li, E.A. Sabelnikova, B.A. Nanaeva, M.Yu. Timanovskaya, T.A. Kosacheva, N.A. Fadeeva, K.A. Nikolskaya, E.Yu. Zhulina, N.V. Kamzarakova, A.I. Parfenov
Russian Journal of Evidence-Based Gastroenterology.2023; 12(3): 29. CrossRef
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial
William J. Sandborn, Rory Rebuck, Yuhua Wang, Bin Zou, Omoniyi J. Adedokun, Christopher Gasink, Bruce E. Sands, Stephen B. Hanauer, Stephan Targan, Subrata Ghosh, Willem J.S. de Villiers, Jean-Frederic Colombel, Brian G. Feagan, John P. Lynch
Clinical Gastroenterology and Hepatology.2022; 20(3): 578. CrossRef
Monitoring frequency of interferon gamma release assay for tuberculosis surveillance following infliximab therapy in patients with Crohn's disease
Qin Yu Yang, Yi Juan Liu, Ye Xu, Lin Zhang, Cheng Dang Wang
Journal of Digestive Diseases.2021; 22(8): 473. CrossRef
Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy
Jihye Kim, Jong Pil Im, Jae-Joon Yim, Chang Kyun Lee, Dong Il Park, Chang Soo Eun, Sung-Ae Jung, Jeong Eun Shin, Kang-Moon Lee, Jae Hee Cheon
The Korean Journal of Gastroenterology.2020; 75(1): 29. CrossRef
Increased Risk of Herpes Zoster in Young and Metabolically Healthy Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
Hosim Soh, Jaeyoung Chun, Kyungdo Han, Seona Park, Gukhwan Choi, Jihye Kim, Jooyoung Lee, Jong Pil Im, Joo Sung Kim
Gut and Liver.2019; 13(3): 333. CrossRef
Discontinuation of Biological Treatments in Inflammatory Bowel Disease
Shomron Ben-Horin, Ren Mao, Yun Qiu, Minhu Chen
Journal of Clinical Gastroenterology.2018; 52(1): 6. CrossRef
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
Intestinal Research.2018; 16(1): 17. CrossRef
Novel treatments for inflammatory bowel disease
Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
The Korean Journal of Internal Medicine.2018; 33(1): 20. CrossRef
Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
Intestinal Research.2018; 16(3): 400. CrossRef
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 2: Management
Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin‐Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
Journal of Gastroenterology and Hepatology.2018; 33(1): 30. CrossRef
Changing treatment paradigms for the management of inflammatory bowel disease
Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
The Korean Journal of Internal Medicine.2018; 33(1): 28. CrossRef
Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease
Jieun Kang, Dae Hyun Jeong, Minkyu Han, Suk-Kyun Yang, Jeong-Sik Byeon, Byong Duk Ye, Sang Hyoung Park, Sung Wook Hwang, Tae Sun Shim, Kyung-Wook Jo
Journal of Korean Medical Science.2018;[Epub] CrossRef
CD8 + CD28 + /CD8 + CD28 − T cell equilibrium can predict the active stage for patients with inflammatory bowel disease
Shi-xue Dai, Hong-xiang Gu, Qian-yi Lin, Shao-zhuo Huang, Tiao-si Xing, Qing-fang Zhang, Gang Wu, Min-hua Chen, Wan-er Tan, Hong-jian Jian, Zhong-wen Zheng, Tao Zhong, Min-hai Zhang, Xing-fang Cheng, Peng Huang, Guang-jie Liao, Wei-hong Sha
Clinics and Research in Hepatology and Gastroenterology.2017; 41(6): 693. CrossRef

6,058 View
72 Download
16 Web of Science
14 Crossref

Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan: Shunsuke Komoto, Satoshi Motoya, Yuji Nishiwaki, Toshiyuki Matsui, Reiko Kunisaki, Katsuyoshi Matsuoka, Naoki Yoshimura, Takashi Kagaya, Makoto Naganuma, Nobuyuki Hida, Mamoru Watanabe, Toshifumi Hibi, Yasuo Suzuki, Soichiro Miura, Ryota Hokari; Intest Res 2016;14(2):139-145. Published online April 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.2.139

Abstract PDF PubReader ePub

Background/Aims

Anti-tumor necrosis factor drugs (anti-TNF) and thiopurines are important treatment options in patients with inflammatory bowel disease (IBD), including during pregnancy. However, there are limited data on the benefit/risk profile of anti-TNF and thiopurines during pregnancy in Asia. The aim of this study was to analyze pregnancy outcomes of female Japanese IBD patients treated with anti-TNF and/or thiopurines.

Methods

This cross-sectional study assessed pregnancy outcomes in 72 women with IBD. Pregnancy outcomes were compared among 31 pregnancies without exposure to infliximab (IFX), adalimumab (ADA), or thiopurines; 24 pregnancies with exposure to anti-TNF treatment (23 IFX, 1 ADA); 7 pregnancies with exposure to thiopurines alone; and 10 pregnancies with exposure to both IFX and thiopurines.

Results

Thirty-five of the 41 pregnancies (85.3%) that were exposed to anti-TNF treatment and/or thiopurines resulted in live births after a median gestational period of 38 weeks. Of the 35 live births, 3 involved premature deliveries; 7, low birth weight; and 1, a congenital abnormality. There were 6 spontaneous abortions in pregnancies that were exposed to anti-TNF treatment (17.7%). Pregnancy outcomes among the 4 groups were similar, except for the rate of spontaneous abortions (P =0.037).

Conclusions

Exposure to anti-TNF treatment or thiopurines during pregnancy was not related to a higher incidence of adverse pregnancy outcomes in Japanese IBD patients except for spontaneous abortion.

Citations

Citations to this article as recorded by

Ulcerative Colitis in Pregnancy: A Japanese Multicenter Cohort Study Focusing on Their Mutual Influence
Yuichi Shimodate, Akiko Shiotani, Ken-ichi Tarumi, Hiroshi Matsumoto, Osamu Handa, Noriaki Tomioka, Naoyuki Nishimura, Kazuhiro Matsueda, Hirokazu Mouri, Motowo Mizuno
Internal Medicine.2025; 64(11): 1633. CrossRef
North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations
Raed Alhusayen, Serena Dienes, Megan Lam, Afsaneh Alavi, Ali Alikhan, Maria Aleshin, Emad Bahashwan, Steve Daveluy, Noah Goldfarb, Amit Garg, Wayne Gulliver, Tarannum Jaleel, Alexa B. Kimball, Mark G. Kirchhof, Joslyn Kirby, Joi Lenczowski, Hadar Lev-Tov,
Journal of the American Academy of Dermatology.2025; 92(4): 825. CrossRef
A retrospective study of neonatal and pregnancy outcomes in pregnant women suffering from inflammatory arthropathy treated with adalimumab
Navid Najarpour, Elham Rajaei, Karim Mowla, Alireza Ghanbaran
Revista Colombiana de Reumatología.2024; 31(3): 290. CrossRef
Anti-tumor necrosis factor-α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review
Wei Huang, Xinxing Zhang, Li Zhang, Xiaosong Dai, Heping Chen, Qin Xie
BMC Pregnancy and Childbirth.2024;[Epub] CrossRef
A retrospective study of neonatal and pregnancy outcomes in pregnant women suffering from inflammatory arthropathy treated with adalimumab
Navid Najarpour, Elham Rajaei, Karim Mowla, Alireza Ghanbaran
Revista Colombiana de Reumatología (English Edition).2024; 31(3): 290. CrossRef
The treatment of inflammatory bowel disease with monoclonal antibodies in Asia
Yu Chen, Guolin Zhang, Yuewen Yang, Shuangshuang Zhang, Haozheng Jiang, Kang Tian, Arenbaoligao, Dapeng Chen
Biomedicine & Pharmacotherapy.2023; 157: 114081. CrossRef
Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy
Nahla A. Azzam, Abdulelah Almutairdi, Hajer Y. Almudaiheem, Turki AlAmeel, Shakir A. Bakkari, Othman R. Alharbi, Khalidah A. Alenzi, Maha A. AlMolaiki, Bedor A. Al-Omari, Rayan G. Albarakati, Ahmed H. Al-Jedai, Omar I. Saadah, Majid A. Almadi, Badr Al-Baw
Saudi Journal of Gastroenterology.2023;[Epub] CrossRef
Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis
Ole Haagen Nielsen, John Mark Gubatan, Carsten Bogh Juhl, Sarah Elizabeth Streett, Cynthia Maxwell
Clinical Gastroenterology and Hepatology.2022; 20(1): 74. CrossRef
British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids
Mark D Russell, Mrinalini Dey, Julia Flint, Philippa Davie, Alexander Allen, Amy Crossley, Margreta Frishman, Mary Gayed, Kenneth Hodson, Munther Khamashta, Louise Moore, Sonia Panchal, Madeleine Piper, Clare Reid, Katherine Saxby, Karen Schreiber, Naz Se
Rheumatology.2022;[Epub] CrossRef
Association between Thiopurines Use and Pregnancy Outcomes in Female Patients with Inflammatory Bowel Disease: A Meta-Analysis
Yang Zhang, Dandan Li, Heng Guo, Weina Wang, Xingang Li, Su Shen
Current Pharmaceutical Design.2021; 27(19): 2317. CrossRef
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Anja Geldhof, Jennifer Slater, Michael Clark, Urmila Chandran, Danielle Coppola
Drug Safety.2020; 43(2): 147. CrossRef
The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
Eun-Jung Park, Hyungjin Kim, Seung Min Jung, Yoon-Kyoung Sung, Han Joo Baek, Jisoo Lee
The Korean Journal of Internal Medicine.2020; 35(1): 41. CrossRef
The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus
Eun-Jung Park, Hyungjin Kim, Seung Min Jung, Yoon-Kyoung Sung, Han Joo Baek, Jisoo Lee
Journal of Rheumatic Diseases.2020; 27(1): 4. CrossRef
Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies
Nicole W Tsao, Nevena Rebic, Larry D Lynd, Mary A De Vera
Rheumatology.2020; 59(8): 1808. CrossRef
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur, H. J. M. J. Crijns
Drugs.2020; 80(16): 1699. CrossRef
Pregnancy and Neuromyelitis Optica Spectrum Disorder – Reciprocal Effects and Practical Recommendations: A Systematic Review
Rohan D'Souza, Danielle Wuebbolt, Katarina Andrejevic, Rizwana Ashraf, Vanessa Nguyen, Nusrat Zaffar, Dalia Rotstein, Ahraaz Wyne
Frontiers in Neurology.2020;[Epub] CrossRef
Relationship between the Clinical Course of Ulcerative Colitis during Pregnancy and the Outcomes of Pregnancy: A Retrospective Evaluation
Ayumi Ito, Bunei Iizuka, Teppei Omori, Shinichi Nakamura, Katsutoshi Tokushige
Internal Medicine.2018; 57(2): 159. CrossRef
The use of biologics and small molecules in pregnant patients with rheumatic diseases
Maria Gerosa, Lorenza Maria Argolini, Carolina Artusi, Cecilia Beatrice Chighizola
Expert Review of Clinical Pharmacology.2018; 11(10): 987. CrossRef
Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease
Ji Min Lee, Yoon Jae Kim, Kang-Moon Lee, Hyuk Yoon, Bo-In Lee, Dae Bum Kim, Donghoon Kang
Scandinavian Journal of Gastroenterology.2018; 53(10-11): 1280. CrossRef
Impact of inflammatory bowel disease activity and thiopurine therapy on birth weight: A meta-analysis
Begoña Gonzalez-Suarez, Shreyashee Sengupta, Alan C Moss
World Journal of Gastroenterology.2017; 23(45): 8082. CrossRef
Maternal and fetal outcomes in pregnant Japanese women with inflammatory bowel disease: our experience with a series of 23 cases
Naoki Minami, Minoru Matsuura, Yorimitsu Koshikawa, Satoshi Yamada, Yusuke Honzawa, Shuji Yamamoto, Hiroshi Nakase
Intestinal Research.2017; 15(1): 90. CrossRef
Concerns in pregnancy and childbirth of women with inflammatory bowel disease
Sung-Ae Jung
Intestinal Research.2016; 14(2): 107. CrossRef
Common Adverse Effects of Anti-TNF Agents on Gestation
Zacharias Fasoulakis, Panagiotis Antsaklis, Nikolaos Galanopoulos, Emmanuel Kontomanolis
Obstetrics and Gynecology International.2016; 2016: 1. CrossRef

7,336 View
80 Download
25 Web of Science
23 Crossref

Spectrum of chronic small bowel diarrhea with malabsorption in Indian subcontinent: is the trend really changing?: Nirav Pipaliya, Meghraj Ingle, Chetan Rathi, Prateik Poddar, Nilesh Pandav, Prabha Sawant; Intest Res 2016;14(1):75-82. Published online January 26, 2016; DOI: https://doi.org/10.5217/ir.2016.14.1.75

Abstract PDF PubReader ePub

Background/Aims

This study aimed to document the recent etiological spectrum of chronic diarrhea with malabsorption and also to compare features that differentiate tropical sprue from parasitic infections, the two most common etiologies of malabsorption in the tropics.

Methods

We analyzed 203 consecutive patients with malabsorption. The etiological spectrum and factors that differentiated tropical sprue from parasitic infections were analyzed.

Results

The most common etiology was tropical sprue (n=98, 48.3%) followed by parasitic infections (n=25, 12.3%) and tuberculosis (n=22, 10.8%). Other causes were immunodeficiency (n=15, 7.3%; 12 with human immunodeficiency virus and 3 with hypogammaglobulinemia), celiac disease (n=11, 5.4%), Crohn's disease (n=11, 5.4%), small intestinal bacterial overgrowth (n=11, 5.4%), hyperthyroidism (n=4, 1.9%), diabetic diarrhea (n=4, 1.9%), systemic lupus erythematosus (n=3, 1.4%), metastatic carcinoid (n=1, 0.5%) and Burkitt's lymphoma (n=1, 0.5%). On multivariate analysis, features that best differentiated tropical sprue from parasitic infections were larger stool volume (P=0.009), severe weight loss (P=0.02), knuckle hyperpigmentation (P=0.008), low serum B12 levels (P=0.05), high mean corpuscular volume (P=0.003), reduced height or scalloping of the duodenal folds on endoscopy (P=0.003) and villous atrophy on histology (P=0.04). Presence of upper gastrointestinal (GI) symptoms like bloating, nausea and vomiting predicted parasitic infections (P=0.01).

Conclusions

Tropical sprue and parasitic infections still dominate the spectrum of malabsorption in India. Severe symptoms and florid malabsorption indicate tropical sprue while the presence of upper GI symptoms indicates parasitic infections.

Citations

Citations to this article as recorded by

The etiological profile of chronic organic non-bloody diarrhea in India: Emergence of inflammatory bowel disease as a dominant cause
Prachi Daga, Amarender Singh Puri, Lipika Lipi, Sumit Bhatia, Randhir Sud
Indian Journal of Gastroenterology.2025; 44(2): 181. CrossRef
Inflammatory Bowel Disease in Children
Asha Jois, George Alex
Indian Journal of Pediatrics.2024; 91(5): 490. CrossRef
The etiological profile of chronic organic non-bloody diarrhea in India: A closer look
Uday C. Ghoshal, Subhamoy Das, Mahesh K. Goenka
Indian Journal of Gastroenterology.2024;[Epub] CrossRef
Enterotoxigenic Escherichia coli heat-labile toxin drives enteropathic changes in small intestinal epithelia
Alaullah Sheikh, Brunda Tumala, Tim J. Vickers, John C. Martin, Bruce A. Rosa, Subrata Sabui, Supratim Basu, Rita D. Simoes, Makedonka Mitreva, Chad Storer, Erik Tyksen, Richard D. Head, Wandy Beatty, Hamid M. Said, James M. Fleckenstein
Nature Communications.2022;[Epub] CrossRef
Acute Bacterial Gastroenteritis
James M. Fleckenstein, F. Matthew Kuhlmann, Alaullah Sheikh
Gastroenterology Clinics of North America.2021; 50(2): 283. CrossRef
Clinical, endoscopic, and histological differentiation between celiac disease and tropical sprue: A systematic review
Pragya Sharma, Vandana Baloda, Gaurav PS Gahlot, Alka Singh, Ritu Mehta, Sreenivas Vishnubathla, Kulwant Kapoor, Vineet Ahuja, Siddhartha Datta Gupta, Govind K Makharia, Prasenjit Das
Journal of Gastroenterology and Hepatology.2019; 34(1): 74. CrossRef
What makes non-cirrhotic portal hypertension a common disease in India? Analysis for environmental factors
Ashish Goel, Banumathi Ramakrishna, Uday Zachariah, K.G. Sajith, Deepak K. Burad, Thomas A. Kodiatte, Shyamkumar N. Keshava, K.A. Balasubramanian, Elwyn Elias, C.E. Eapen
Indian Journal of Medical Research.2019; 149(4): 468. CrossRef
Nutritional Approach in Tropical Sprue Patients
Stefanie Knebusch Toriello
Current Tropical Medicine Reports.2018; 5(3): 211. CrossRef

11,240 View
114 Download
9 Web of Science
8 Crossref

The role of capsule endoscopy in etiological diagnosis and management of obscure gastrointestinal bleeding: Vikas Pandey, Meghraj Ingle, Nilesh Pandav, Pathik Parikh, Jignesh Patel, Aniruddha Phadke, Prabha Sawant; Intest Res 2016;14(1):69-74. Published online January 26, 2016; DOI: https://doi.org/10.5217/ir.2016.14.1.69

Abstract PDF PubReader ePub

Background/Aims

To investigate the various etiologies, yields, and effects of capsule endoscopy (CE) on management and complications, along with follow up of patients with obscure gastrointestinal (GI) bleeding.

Methods

The study group of patients included those having obscure, overt, or occult GI bleeding. The findings were categorized as (A) obvious/definitive, (B) equivocal, or (C) negative. Any significant alteration in patient management post CE in the form of drug or surgical intervention was noted.

Results

Total patients included in the study were 68 (48 males and 20 females). The ratio of male:female was 2.4:1. The age ranged between 16 years to 77 years. Mean age for males was 62±14 years, for females 58±16 years. The total yield of CE with definitive lesions was in 44/68 (65.0%) of patients. In descending order (A) angiodysplasia 16/68 (23.53%), (B) Crohn's disease 10/68 (14.70%), (C) non-steroidal anti-inflammatory drug enteropathy 8/68 (11.76%), (D) small bowel ulcers 4/68 (5.88%), (E) jejunal and ileal polyps 2/68 (2.94%), (F) intestinal lymphangiectasis 2/68 (2.94%), and (G) ileal hemangiomas 2/68 (2.94%) were followed. Equivocal findings 12/68 (17.65%) and negative study 12/68 (17.65%) was found. Complications in the form of capsule retention in the distal ileum were noted in 2/68 (2.94%) subjects. Statistically, there was a higher probability of finding the etiology if the CE was done during an episode of bleeding.

Conclusions

CE plays an important role in diagnosing etiologies of obscure GI bleeding. Its role in influencing the management outcome is vital.

Citations

Citations to this article as recorded by

Capsule endoscopy for obscure gastrointestinal bleed in the tropics: A single-center experience on 350 patients
Uday C. Ghoshal, Piyush Mishra, Akash Mathur, Sai Prathap Reddy, Bushra Fatima, Asha Misra
Indian Journal of Gastroenterology.2024; 43(5): 1045. CrossRef
Capsule endoscopy for small bowel bleed: Current update
Uday C. Ghoshal, Akash Roy, Mahesh K. Goenka
Indian Journal of Gastroenterology.2024; 43(5): 896. CrossRef
An intelligent intestinal bleeding diagnosis and treatment capsule system based on color recognition
Panpan Qiao, Luo Yu, Hongying Liu, Xueping Yan, Xitian Pi
Biomedical Microdevices.2023;[Epub] CrossRef
Systematic review and meta‐analysis of the diagnostic and therapeutic yield of small bowel endoscopy in patients with overt small bowel bleeding
Genta Uchida, Masanao Nakamura, Takeshi Yamamura, Kazuhiro Furukawa, Hiroki Kawashima, Takashi Honda, Masatoshi Ishigami, Mitsuhiro Fujishiro
Digestive Endoscopy.2021; 33(1): 66. CrossRef
Comparison in the Diagnostic Yield between “Pillcam SB3” Capsule Endoscopy and “OMOM Smart Capsule 2” in Small Bowel Bleeding: A Randomized Head-to-Head Study
Gerardo Blanco-Velasco, Raúl Antonio Zamarripa-Mottú, Omar Michel Solórzano-Pineda, Miguel Mascarenhas-Saraiva, Juan Manuel Blancas-Valencia, Oscar Victor Hernández-Mondragón
Digestive Diseases.2021; 39(3): 211. CrossRef
Heterotopia de mucosa gástrica en intestino delgado, hallazgo en videocápsula endoscópica. Reporte de caso
Santiago Castaño, Natalia Calvache, Mauricio Sepúlveda
Revista Colombiana de Gastroenterología.2019; 34(3): 314. CrossRef
Meta-analysis shows similar re-bleeding rates among Western and Eastern populations after index video capsule endoscopy
Georgios Tziatzios, Paraskevas Gkolfakis, Cesare Hassan, Ervin Toth, Angelo Zullo, Anastasios Koulaouzidis, George D. Dimitriadis, Konstantinos Triantafyllou
Digestive and Liver Disease.2018; 50(3): 226. CrossRef
Lanreotide in the management of small bowel angioectasias: seven-year data from a tertiary centre
S. Chetcuti Zammit, D. S. Sanders, R. Sidhu
Scandinavian Journal of Gastroenterology.2017; : 1. CrossRef
Role of capsule endoscopy in suspected or established Crohn's disease in real practice
Hyun Joo Jang
Intestinal Research.2017; 15(4): 431. CrossRef
The Role of Dynamic Contrast-enhanced Multidetector-row Computed Tomography in Diagnosis of Obscure Gastrointestinal Bleeding
Jee Hyun Kim, Jong Pil Im
The Korean Journal of Gastroenterology.2016; 67(4): 165. CrossRef

6,476 View
61 Download
10 Web of Science
10 Crossref

Gastric lesions in patients with Crohn's disease in Korea: a multicenter study: Hoonsub So, Byong Duk Ye, Young Soo Park, Jihun Kim, Joo Sung Kim, Won Moon, Kang-Moon Lee, You Sun Kim, Bora Keum, Seong-Eun Kim, Kyeong Ok Kim, Eun Soo Kim, Chang Kyun Lee, Sung Pil Hong, Jong Pil Im, Ja Seol Koo, Chang Hwan Choi, Jeong Eun Shin, Bo In Lee, Kyu Chan Huh, Young-Ho Kim, Hyun-Soo Kim, Young Sook Park, Dong Soo Han; Intest Res 2016;14(1):60-68. Published online January 26, 2016; DOI: https://doi.org/10.5217/ir.2016.14.1.60

Abstract PDF PubReader ePub

Background/Aims

Gastric pathology and Helicobacter pylori (H. pylori) infection among Asian patients with Crohn's disease (CD) are still unclear. We evaluated gastric histologic features and frequency of H. pylori infection in Korean patients with CD.

Methods

Among 492 patients with CD receiving upper gastrointestinal (GI) endoscopic evaluation in 19 Korean hospitals, we evaluated the endoscopic findings and gastric histopathologic features of 47 patients for our study. Histopathologic classification was performed using gastric biopsy tissues, and H. pylori infection was determined using the rapid urease test and histology.

Results

There were 36 men (76.6%), and the median age of patients at the time of upper GI endoscopy was 23.8 years (range, 14.2–60.5). For CD phenotype, ileocolonic disease was observed in 38 patients (80.9%), and non-stricturing, non-penetrating disease in 31 patients (66.0%). Twenty-eight patients (59.6%) complained of upper GI symptoms. Erosive gastritis was the most common gross gastric feature (66.0%). Histopathologically, H. pylori-negative chronic active gastritis (38.3%) was the most frequent finding. H. pylori testing was positive in 11 patients (23.4%), and gastric noncaseating granulomata were detected in 4 patients (8.5%). Gastric noncaseating granuloma showed a statistically significant association with perianal abscess/fistula (P=0.0496).

Conclusions

H. pylori-negative chronic active gastritis appears to be frequent among Korean patients with CD. The frequency of H. pylori infection was comparable with previous studies. An association with perianal complications suggests a prognostic value for gastric noncaseating granuloma in patients with CD.

Citations

Citations to this article as recorded by

Endoscopic findings in the upper gastrointestinal tract in patients with Crohn’s disease are common, highly specific, and associated with chronic gastritis
Katarzyna Graca-Pakulska, Wojciech Błogowski, Iwona Zawada, Anna Deskur, Krzysztof Dąbkowski, Elżbieta Urasińska, Teresa Starzyńska
Scientific Reports.2023;[Epub] CrossRef
Detection Rates of Non-Cavitary Epithelioid Cell Granuloma by Gastrointestinal Biopsy in Patients with Treatment-Naïve Crohn’s Disease
Katsuya Endo, Yoko Kawakami, Yuki Yoshino, Shiho Kondo, Daisuke Fukushi, Atsuko Takasu, Takayuki Kogure, Morihisa Hirota, Kazuhiro Murakami, Kennichi Satoh
Inflammatory Intestinal Diseases.2023; 8(3): 105. CrossRef
Beyond Helicobacter: dealing with other variants of gastritis—an algorithmic approach
Hala El‐Zimaity, Robert H Riddell
Histopathology.2021; 78(1): 48. CrossRef
Endoscopic and Histopathological Findings of the Esophagus, Stomach, and Duodenum in Patients with Crohn’s Disease from a Reference Center in Bahia, Brazil
Andrea Maia Pimentel, Luiz Antônio Rodrigues de Freitas, Rita de Cássia Reis Cruz, Isaac Neri de Novais Silva, Laíla Damasceno Andrade, Paola Nascimento Marques, Júlia Cordeiro Braga, Flora Maria Lorenzo Fortes, Katia Rejane Marques Brito, Jaciane Araújo
Clinics and Practice.2021; 11(2): 374. CrossRef
The gastric microbiota in patients with Crohn’s disease; a preliminary study
Jerzy Ostrowski, Maria Kulecka, Iwona Zawada, Natalia Żeber-Lubecka, Agnieszka Paziewska, Katarzyna Graca-Pakulska, Krzysztof Dąbkowski, Karolina Skubisz, Patrycja Cybula, Filip Ambrożkiewicz, Elżbieta Urasińska, Michał Mikula, Teresa Starzyńska
Scientific Reports.2021;[Epub] CrossRef
Associations between the Presence of Granulomata and Disease Phenotype and Outcomes in Children Diagnosed with Crohn’s Disease
Laura Appleton, Euan Watt, Fiona Jagger, Richard Hansen, Richard B. Gearry, Andrew S. Day
Gastrointestinal Disorders.2020; 2(2): 164. CrossRef
Ovarian Crohn’s Disease: A Case Report and Review of the Literature
Hamza Mohammed, Rana Bokhary, Mohammed Nassif, Mahmoud Mosli, Haruhiko Sugimura
Case Reports in Gastrointestinal Medicine.2020; 2020: 1. CrossRef
Crohn’s disease of esophagus, stomach and duodenum
Andréa Maia Pimentel, Raquel Rocha, Genoile Oliveira Santana
World Journal of Gastrointestinal Pharmacology and Therapeutics.2019; 10(2): 35. CrossRef
Prognostic significance of granulomas in children with Crohn’s disease
Benjamin Rothschild, Firas Rinawi, Yonatan Herman, Osnat Nir, Raanan Shamir, Amit Assa
Scandinavian Journal of Gastroenterology.2017; 52(6-7): 716. CrossRef
Endoscopic Bamboo Joint-like Appearance of the Stomach in Crohn's Disease
Kwang Il Seo, Won Moon
The Korean Journal of Gastroenterology.2017; 69(2): 151. CrossRef
Characteristics of Upper Gastrointestinal Tract Involvement in Korean Pediatric Crohn's Disease: A Multicenter Study
Ji Hyoung Park, Hye Na Nam, Ji-Hyuk Lee, Jeana Hong, Dae Yong Yi, Eell Ryoo, In Sang Jeon, Hann Tchah
Pediatric Gastroenterology, Hepatology & Nutrition.2017; 20(4): 227. CrossRef
Increased duodenal expression of miR-146a and -155 in pediatric Crohn’s disease
Dániel Szűcs, Nóra Judit Béres, Réka Rokonay, Kriszta Boros, Katalin Borka, Zoltán Kiss, András Arató, Attila J Szabó, Ádám Vannay, Erna Sziksz, Csaba Bereczki, Gábor Veres
World Journal of Gastroenterology.2016; 22(26): 6027. CrossRef

7,727 View
70 Download
10 Web of Science
12 Crossref

Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study: Yasuo Suzuki, Mitsuo Iida, Hiroaki Ito, Isamu Saida, Toshifumi Hibi; Intest Res 2016;14(1):50-59. Published online January 26, 2016; DOI: https://doi.org/10.5217/ir.2016.14.1.50

Abstract PDF PubReader ePub

Background/Aims

The therapeutic effect of mesalamine is considered to be dose-dependent; however, no consensus has been reached regarding the optimal doses for individual patients. This study aimed to provide new insight for dose optimization using two doses of pH-dependent release mesalamine for induction of remission of moderately active ulcerative colitis (UC).

Methods

In a multicenter, double-blind, randomized study, 110 patients with moderately active UC were assigned to two groups after treatment with a constant dose of mesalamine. Fifty-five patients were treated with a pH-dependent release formulation of 3.6 or 4.8 g/day for 8 weeks. The primary endpoint was a decrease in the UC disease activity index (UCDAI) adjusted by covariates.

Results

In the full analysis set (n=110), the mean decrease in UCDAI was 3.1 in the 3.6 g/day group and 3.4 in the 4.8 g/day group (P>0.05). In a subgroup analysis, the effectiveness of the 4.8 g/day dose was greater in particular populations, such as those who had been previously treated with a lower dose of mesalamine and those with more severe disease. The safety was comparable between the two groups.

Conclusions

The results suggest that treatment with pH-dependent release mesalamine at either 3.6 or 4.8 g/day was effective and safe for the induction of remission in patients with moderately active UC. However, the patients receiving mesalamine at 2.4 g/day but in whom the therapeutic effect is not sufficient and having more severe symptoms (UCDAI 9-10), benefit from higher doses of mesalamine compared to others.

Citations

Citations to this article as recorded by

Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kir
Intestinal Research.2020; 18(4): 355. CrossRef
Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
Intestinal Research.2018; 16(3): 400. CrossRef
Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
Haruhiko Ogata, Nobuo Aoyama, Seiichi Mizushima, Atsushi Hagino, Toshifumi Hibi
Intestinal Research.2017; 15(3): 368. CrossRef
Remission endpoints in ulcerative colitis: A systematic review
Maki Jitsumura, Rory Frederick Kokelaar, Dean Anthony Harris
World Journal of Meta-Analysis.2017; 5(4): 85. CrossRef
Potential Benefits of Dietary Fibre Intervention in Inflammatory Bowel Disease
Celestine Wong, Philip Harris, Lynnette Ferguson
International Journal of Molecular Sciences.2016; 17(6): 919. CrossRef
What is the real-life maintenance mesalazine dose in ulcerative colitis?
Alicia Algaba, Iván Guerra, Ana García García de Paredes, María Hernández Tejero, Carlos Ferre, Daniel Bonillo, Lara Aguilera, Antonio López-Sanromán, Fernando Bermejo
Revista Española de Enfermedades Digestivas.2016;[Epub] CrossRef

6,000 View
66 Download
6 Web of Science
6 Crossref

The prevalence and clinical characteristics of anemia in Korean patients with inflammatory bowel disease: Dae Sung Lee, Ki Bae Bang, Ji Yeon Kim, Yoon Suk Jung, Jung Ho Park, Hong Joo Kim, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Kyu Young Choi, Dong Il Park; Intest Res 2016;14(1):43-49. Published online January 26, 2016; DOI: https://doi.org/10.5217/ir.2016.14.1.43

Abstract PDF PubReader ePub

Background/Aims

Quality of life is closely related to anemia in patients with inflammatory bowel disease (IBD). Several studies have reported on anemia in patients with IBD in Western countries. This study investigated the prevalence and clinical characteristics of anemia in Korean patients with IBD.

Methods

We reviewed the medical records of 92 patients with ulcerative colitis (UC) and 76 patients with Crohn's disease (CD) who were followed regularly at a single tertiary medical center in Korea between January 2003 and December 2012. Hemoglobin (Hb) thresholds used to define anemia were <13.0 g/dL in men and <12.0 g/dL in women according to the World Health Organization criteria. We chose the lowest Hb level in each year as a representative value because Hb levels changed at each examination and anemia was associated with disease deterioration. The relationship between clinical variables and lowest Hb level was assessed.

Results

The prevalence of anemia was 36.3% in patients with UC and 41.6% in patients with CD. Anemia in patients with CD was associated with hospital admission, 5-aminosalicylate (5-ASA) and infliximab treatment in men. Anemia in patients with UC was associated with hospital admission, oral steroid use, thiopurine and infliximab treatment in men.

Conclusions

The prevalence of anemia in Korean patients with IBD was comparable to that of patients in Western countries. Anemia was associated with male patients with CD who were admitted to the hospital and received medications including 5-ASA and infliximab, and men with UC who were admitted to the hospital and received medications including oral steroids, thiopurine and infliximab.

Citations

Citations to this article as recorded by

Clinical characteristics and north-south differences of inflammatory bowel disease in China: A cross-sectional study and meta-analysis
Qi Liang, Bo Qu, Chunye Li, Yue Hu, Chunyi Yang, Tingting Yang, Yuzhu Di, Hui Li
Frigid Zone Medicine.2024; 4(1): 23. CrossRef
Clinical and Laboratory Characteristics of Anaemia in Hospitalized Patients with Inflammatory Bowel Disease
Małgorzata Woźniak, Anna Borkowska, Marta Jastrzębska, Marcin Sochal, Ewa Małecka-Wojciesko, Renata Talar-Wojnarowska
Journal of Clinical Medicine.2023; 12(7): 2447. CrossRef
Ferric carboxymaltose for anemia in Crohn’s disease patients at a tertiary center: A retrospective observational cohort study
Natália Souza Nunes Siqueira, Livia Bitencourt Pascoal, Bruno Lima Rodrigues, Marina Moreira de Castro, Alan Sidnei Corrêa Martins, Dante Orsetti Silva Araújo, Luis Eduardo Miani Gomes, Michel Gardere Camargo, Maria de Lourdes Setsuko Ayrizono, Raquel Fra
World Journal of Clinical Cases.2023; 11(12): 2740. CrossRef
ANEMIA AND IRON DEFICIENCY IN INFLAMMATORY BOWEL DISEASE PATIENTS IN A REFERRAL CENTER IN BRAZIL: PREVALENCE AND RISK FACTORS
Rogério Serafim PARRA, Marley Ribeiro FEITOSA, Sandro da Costa FERREIRA, José Joaquim Ribeiro da ROCHA, Luiz Ernesto de Almeida TRONCON, Omar FÉRES
Arquivos de Gastroenterologia.2020; 57(3): 272. CrossRef
Frequency, types, and treatment of anemia in Turkish patients with inflammatory bowel disease
Göksel Bengi, Hatice Keyvan, Seda Bayrak Durmaz, Hale Akpınar
World Journal of Gastroenterology.2018; 24(36): 4186. CrossRef
Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
Intestinal Research.2018; 16(3): 400. CrossRef
Should asymptomatic young men with iron deficiency anemia necessarily undergo endoscopy?
Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn, Kyuyong Choi, Yoon Suk Jung
The Korean Journal of Internal Medicine.2018; 33(6): 1084. CrossRef
Anemia at the time of diagnosis of inflammatory bowel disease: Prevalence and associated factors in adolescent and adult patients
Alfredo J. Lucendo, Ángel Arias, Óscar Roncero, Daniel Hervías, Cristina Verdejo, Carmen Naveas-Polo, Abdelmouneim Bouhmidi, Rufo Lorente, Luis Miguel Alcázar, Irina Salueña, Julio A. García-Quiñones, María Jesús Carrillo-Ramos
Digestive and Liver Disease.2017; 49(4): 405. CrossRef

5,913 View
66 Download
8 Web of Science
8 Crossref

First
Prev
Page of 18
Next
Last

Original article